CN111269321B - 一种glp-1类似物融合蛋白质 - Google Patents
一种glp-1类似物融合蛋白质 Download PDFInfo
- Publication number
- CN111269321B CN111269321B CN201811472291.9A CN201811472291A CN111269321B CN 111269321 B CN111269321 B CN 111269321B CN 201811472291 A CN201811472291 A CN 201811472291A CN 111269321 B CN111269321 B CN 111269321B
- Authority
- CN
- China
- Prior art keywords
- ser
- leu
- lys
- val
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title claims abstract description 77
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 71
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 71
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 170
- 210000004027 cell Anatomy 0.000 claims description 46
- 239000013598 vector Substances 0.000 claims description 18
- 108060003951 Immunoglobulin Proteins 0.000 claims description 14
- 102000018358 immunoglobulin Human genes 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 20
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 14
- 238000006467 substitution reaction Methods 0.000 abstract description 10
- 238000001727 in vivo Methods 0.000 abstract description 9
- 230000004927 fusion Effects 0.000 abstract description 7
- 238000000338 in vitro Methods 0.000 abstract description 5
- 230000005847 immunogenicity Effects 0.000 abstract description 4
- 208000008589 Obesity Diseases 0.000 abstract description 3
- 235000020824 obesity Nutrition 0.000 abstract description 3
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 229920005989 resin Polymers 0.000 description 143
- 239000011347 resin Substances 0.000 description 143
- 102000004196 processed proteins & peptides Human genes 0.000 description 111
- 239000000243 solution Substances 0.000 description 106
- 229920001184 polypeptide Polymers 0.000 description 105
- 108090000623 proteins and genes Proteins 0.000 description 57
- 125000006239 protecting group Chemical group 0.000 description 50
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 48
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 47
- -1 dolapride Proteins 0.000 description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 41
- 238000002360 preparation method Methods 0.000 description 40
- 238000006243 chemical reaction Methods 0.000 description 39
- 238000000034 method Methods 0.000 description 35
- 229920003180 amino resin Polymers 0.000 description 34
- 102000004169 proteins and genes Human genes 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 210000004369 blood Anatomy 0.000 description 33
- 239000008280 blood Substances 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 33
- 238000000746 purification Methods 0.000 description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 239000000047 product Substances 0.000 description 30
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 30
- 239000012071 phase Substances 0.000 description 29
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 25
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 23
- 238000001914 filtration Methods 0.000 description 23
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 22
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 21
- 108010011459 Exenatide Proteins 0.000 description 21
- LLWQVJNHMYBLLK-CDMKHQONSA-N Gly-Thr-Phe Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLWQVJNHMYBLLK-CDMKHQONSA-N 0.000 description 21
- IVDFVBVIVLJJHR-LKXGYXEUSA-N Thr-Ser-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IVDFVBVIVLJJHR-LKXGYXEUSA-N 0.000 description 21
- 238000005406 washing Methods 0.000 description 21
- AFPFGFUGETYOSY-HGNGGELXSA-N His-Ala-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AFPFGFUGETYOSY-HGNGGELXSA-N 0.000 description 20
- KSCVLGXNQXKUAR-JYJNAYRXSA-N Tyr-Leu-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KSCVLGXNQXKUAR-JYJNAYRXSA-N 0.000 description 20
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 20
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 19
- HWLKHNDRXWTFTN-GUBZILKMSA-N Pro-Pro-Cys Chemical compound C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CS)C(=O)O HWLKHNDRXWTFTN-GUBZILKMSA-N 0.000 description 19
- 108010060199 cysteinylproline Proteins 0.000 description 19
- 238000005086 pumping Methods 0.000 description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 18
- 238000010828 elution Methods 0.000 description 18
- 239000008103 glucose Substances 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 229960001519 exenatide Drugs 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 238000009833 condensation Methods 0.000 description 16
- 230000005494 condensation Effects 0.000 description 16
- 239000012043 crude product Substances 0.000 description 16
- 239000012528 membrane Substances 0.000 description 16
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 15
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 15
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 15
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 15
- JDMKQHSHKJHAHR-UHFFFAOYSA-N Phe-Phe-Leu-Tyr Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=CC=C1 JDMKQHSHKJHAHR-UHFFFAOYSA-N 0.000 description 15
- RWOKVQUCENPXGE-IHRRRGAJSA-N Tyr-Ser-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RWOKVQUCENPXGE-IHRRRGAJSA-N 0.000 description 15
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 15
- 238000010511 deprotection reaction Methods 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 15
- 108010050848 glycylleucine Proteins 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 15
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 15
- 108010052774 valyl-lysyl-glycyl-phenylalanyl-tyrosine Proteins 0.000 description 15
- 239000000872 buffer Substances 0.000 description 14
- 239000011259 mixed solution Substances 0.000 description 14
- 239000007790 solid phase Substances 0.000 description 14
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 13
- 229940095074 cyclic amp Drugs 0.000 description 13
- 235000000346 sugar Nutrition 0.000 description 13
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 12
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 12
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 238000010367 cloning Methods 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 11
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 11
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 11
- 238000003016 alphascreen Methods 0.000 description 11
- 239000011324 bead Substances 0.000 description 11
- 238000011068 loading method Methods 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 108010031719 prolyl-serine Proteins 0.000 description 11
- PUBLUECXJRHTBK-ACZMJKKPSA-N Ala-Glu-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O PUBLUECXJRHTBK-ACZMJKKPSA-N 0.000 description 10
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 10
- YJHKTAMKPGFJCT-NRPADANISA-N Ala-Val-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O YJHKTAMKPGFJCT-NRPADANISA-N 0.000 description 10
- ZUVMUOOHJYNJPP-XIRDDKMYSA-N Arg-Trp-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZUVMUOOHJYNJPP-XIRDDKMYSA-N 0.000 description 10
- WONGRTVAMHFGBE-WDSKDSINSA-N Asn-Gly-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N WONGRTVAMHFGBE-WDSKDSINSA-N 0.000 description 10
- QNNBHTFDFFFHGC-KKUMJFAQSA-N Asn-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QNNBHTFDFFFHGC-KKUMJFAQSA-N 0.000 description 10
- DPNWSMBUYCLEDG-CIUDSAMLSA-N Asp-Lys-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O DPNWSMBUYCLEDG-CIUDSAMLSA-N 0.000 description 10
- DHNWZLGBTPUTQQ-QEJZJMRPSA-N Gln-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N DHNWZLGBTPUTQQ-QEJZJMRPSA-N 0.000 description 10
- SNLOOPZHAQDMJG-CIUDSAMLSA-N Gln-Glu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SNLOOPZHAQDMJG-CIUDSAMLSA-N 0.000 description 10
- ZEEPYMXTJWIMSN-GUBZILKMSA-N Gln-Lys-Ser Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@@H](N)CCC(N)=O ZEEPYMXTJWIMSN-GUBZILKMSA-N 0.000 description 10
- FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 10
- CKOFNWCLWRYUHK-XHNCKOQMSA-N Glu-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CKOFNWCLWRYUHK-XHNCKOQMSA-N 0.000 description 10
- RFDHKPSHTXZKLL-IHRRRGAJSA-N Glu-Gln-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N RFDHKPSHTXZKLL-IHRRRGAJSA-N 0.000 description 10
- UHVIQGKBMXEVGN-WDSKDSINSA-N Glu-Gly-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UHVIQGKBMXEVGN-WDSKDSINSA-N 0.000 description 10
- QDMVXRNLOPTPIE-WDCWCFNPSA-N Glu-Lys-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QDMVXRNLOPTPIE-WDCWCFNPSA-N 0.000 description 10
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 10
- LIXWIUAORXJNBH-QWRGUYRKSA-N Gly-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN LIXWIUAORXJNBH-QWRGUYRKSA-N 0.000 description 10
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 10
- MAABHGXCIBEYQR-XVYDVKMFSA-N His-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N MAABHGXCIBEYQR-XVYDVKMFSA-N 0.000 description 10
- HIAHVKLTHNOENC-HGNGGELXSA-N His-Glu-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HIAHVKLTHNOENC-HGNGGELXSA-N 0.000 description 10
- CSTDQOOBZBAJKE-BWAGICSOSA-N His-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CN=CN2)N)O CSTDQOOBZBAJKE-BWAGICSOSA-N 0.000 description 10
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 10
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 10
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 10
- 241000880493 Leptailurus serval Species 0.000 description 10
- OIARJGNVARWKFP-YUMQZZPRSA-N Leu-Asn-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIARJGNVARWKFP-YUMQZZPRSA-N 0.000 description 10
- BTNXKBVLWJBTNR-SRVKXCTJSA-N Leu-His-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O BTNXKBVLWJBTNR-SRVKXCTJSA-N 0.000 description 10
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 10
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 10
- MWVUEPNEPWMFBD-SRVKXCTJSA-N Lys-Cys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCCCN MWVUEPNEPWMFBD-SRVKXCTJSA-N 0.000 description 10
- ODUQLUADRKMHOZ-JYJNAYRXSA-N Lys-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N)O ODUQLUADRKMHOZ-JYJNAYRXSA-N 0.000 description 10
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 description 10
- LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 10
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 10
- RQILLQOQXLZTCK-KBPBESRZSA-N Lys-Tyr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O RQILLQOQXLZTCK-KBPBESRZSA-N 0.000 description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- IHRFZLQEQVHXFA-RHYQMDGZSA-N Met-Thr-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCCN IHRFZLQEQVHXFA-RHYQMDGZSA-N 0.000 description 10
- JOXIIFVCSATTDH-IHPCNDPISA-N Phe-Asn-Trp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N JOXIIFVCSATTDH-IHPCNDPISA-N 0.000 description 10
- SMFGCTXUBWEPKM-KBPBESRZSA-N Phe-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 SMFGCTXUBWEPKM-KBPBESRZSA-N 0.000 description 10
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 10
- SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 10
- TUYWCHPXKQTISF-LPEHRKFASA-N Pro-Cys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N2CCC[C@@H]2C(=O)O TUYWCHPXKQTISF-LPEHRKFASA-N 0.000 description 10
- UAYHMOIGIQZLFR-NHCYSSNCSA-N Pro-Gln-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UAYHMOIGIQZLFR-NHCYSSNCSA-N 0.000 description 10
- KIPIKSXPPLABPN-CIUDSAMLSA-N Pro-Glu-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 KIPIKSXPPLABPN-CIUDSAMLSA-N 0.000 description 10
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 10
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 10
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 10
- JCLAFVNDBJMLBC-JBDRJPRFSA-N Ser-Ser-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JCLAFVNDBJMLBC-JBDRJPRFSA-N 0.000 description 10
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 10
- RCOUFINCYASMDN-GUBZILKMSA-N Ser-Val-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O RCOUFINCYASMDN-GUBZILKMSA-N 0.000 description 10
- FIFDDJFLNVAVMS-RHYQMDGZSA-N Thr-Leu-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O FIFDDJFLNVAVMS-RHYQMDGZSA-N 0.000 description 10
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 10
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 10
- UDCHKDYNMRJYMI-QEJZJMRPSA-N Trp-Glu-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UDCHKDYNMRJYMI-QEJZJMRPSA-N 0.000 description 10
- PWKMJDQXKCENMF-MEYUZBJRSA-N Tyr-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O PWKMJDQXKCENMF-MEYUZBJRSA-N 0.000 description 10
- SQUMHUZLJDUROQ-YDHLFZDLSA-N Tyr-Val-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O SQUMHUZLJDUROQ-YDHLFZDLSA-N 0.000 description 10
- UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 description 10
- HJSLDXZAZGFPDK-ULQDDVLXSA-N Val-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N HJSLDXZAZGFPDK-ULQDDVLXSA-N 0.000 description 10
- KISFXYYRKKNLOP-IHRRRGAJSA-N Val-Phe-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)O)N KISFXYYRKKNLOP-IHRRRGAJSA-N 0.000 description 10
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 10
- RYHUIHUOYRNNIE-NRPADANISA-N Val-Ser-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N RYHUIHUOYRNNIE-NRPADANISA-N 0.000 description 10
- BZDGLJPROOOUOZ-XGEHTFHBSA-N Val-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N)O BZDGLJPROOOUOZ-XGEHTFHBSA-N 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 108010047857 aspartylglycine Proteins 0.000 description 10
- 238000006482 condensation reaction Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000012065 filter cake Substances 0.000 description 10
- 108010015792 glycyllysine Proteins 0.000 description 10
- 108010077515 glycylproline Proteins 0.000 description 10
- 108010057821 leucylproline Proteins 0.000 description 10
- 108010003700 lysyl aspartic acid Proteins 0.000 description 10
- 108010017391 lysylvaline Proteins 0.000 description 10
- 108010061238 threonyl-glycine Proteins 0.000 description 10
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 10
- 108010044292 tryptophyltyrosine Proteins 0.000 description 10
- 108010051110 tyrosyl-lysine Proteins 0.000 description 10
- 108010027345 wheylin-1 peptide Proteins 0.000 description 10
- YJIUYQKQBBQYHZ-ACZMJKKPSA-N Gln-Ala-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YJIUYQKQBBQYHZ-ACZMJKKPSA-N 0.000 description 9
- DUTMKEAPLLUGNO-JYJNAYRXSA-N Lys-Glu-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DUTMKEAPLLUGNO-JYJNAYRXSA-N 0.000 description 9
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 9
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 9
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 9
- 210000004899 c-terminal region Anatomy 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 9
- 108010053037 kyotorphin Proteins 0.000 description 9
- 230000001376 precipitating effect Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 8
- JDDWRLPTKIOUOF-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-[[4-[2-[bis(4-methylphenyl)methylamino]-2-oxoethoxy]phenyl]-(2,4-dimethoxyphenyl)methyl]carbamate Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(=O)NC(C=2C=CC(C)=CC=2)C=2C=CC(C)=CC=2)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JDDWRLPTKIOUOF-UHFFFAOYSA-N 0.000 description 8
- CNQAFFMNJIQYGX-DRZSPHRISA-N Ala-Phe-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 CNQAFFMNJIQYGX-DRZSPHRISA-N 0.000 description 8
- 238000011033 desalting Methods 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 239000007791 liquid phase Substances 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 239000013014 purified material Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- XXMYDXUIZKNHDT-QNGWXLTQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXMYDXUIZKNHDT-QNGWXLTQSA-N 0.000 description 7
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 7
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 230000005587 bubbling Effects 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 7
- 238000000227 grinding Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- 238000010532 solid phase synthesis reaction Methods 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 230000002194 synthesizing effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 238000001291 vacuum drying Methods 0.000 description 7
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 6
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- DPTBVFUDCPINIP-JURCDPSOSA-N Ile-Ala-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 DPTBVFUDCPINIP-JURCDPSOSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- COEXAQSTZUWMRI-STQMWFEESA-N (2s)-1-[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@H](N)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 COEXAQSTZUWMRI-STQMWFEESA-N 0.000 description 5
- IESDGNYHXIOKRW-YXMSTPNBSA-N (2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-YXMSTPNBSA-N 0.000 description 5
- DIBLBAURNYJYBF-XLXZRNDBSA-N (2s)-2-[[(2s)-2-[[2-[[(2s)-6-amino-2-[[(2s)-2-amino-3-methylbutanoyl]amino]hexanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 DIBLBAURNYJYBF-XLXZRNDBSA-N 0.000 description 5
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 5
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 5
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 5
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 5
- LGCVSPFCFXWUEY-IHPCNDPISA-N Asn-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N LGCVSPFCFXWUEY-IHPCNDPISA-N 0.000 description 5
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 5
- ZXCAQANTQWBICD-DCAQKATOSA-N Cys-Lys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N ZXCAQANTQWBICD-DCAQKATOSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- CSMHMEATMDCQNY-DZKIICNBSA-N Gln-Val-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CSMHMEATMDCQNY-DZKIICNBSA-N 0.000 description 5
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 5
- GLWXKFRTOHKGIT-ACZMJKKPSA-N Glu-Asn-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GLWXKFRTOHKGIT-ACZMJKKPSA-N 0.000 description 5
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 5
- KASDBWKLWJKTLJ-GUBZILKMSA-N Glu-Glu-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O KASDBWKLWJKTLJ-GUBZILKMSA-N 0.000 description 5
- ALMBZBOCGSVSAI-ACZMJKKPSA-N Glu-Ser-Asn Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ALMBZBOCGSVSAI-ACZMJKKPSA-N 0.000 description 5
- QOXDAWODGSIDDI-GUBZILKMSA-N Glu-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N QOXDAWODGSIDDI-GUBZILKMSA-N 0.000 description 5
- MFYLRRCYBBJYPI-JYJNAYRXSA-N Glu-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O MFYLRRCYBBJYPI-JYJNAYRXSA-N 0.000 description 5
- ZALGPUWUVHOGAE-GVXVVHGQSA-N Glu-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZALGPUWUVHOGAE-GVXVVHGQSA-N 0.000 description 5
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 5
- VSVZIEVNUYDAFR-YUMQZZPRSA-N Gly-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN VSVZIEVNUYDAFR-YUMQZZPRSA-N 0.000 description 5
- GRIRDMVMJJDZKV-RCOVLWMOSA-N Gly-Asn-Val Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O GRIRDMVMJJDZKV-RCOVLWMOSA-N 0.000 description 5
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 5
- UUYBFNKHOCJCHT-VHSXEESVSA-N Gly-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN UUYBFNKHOCJCHT-VHSXEESVSA-N 0.000 description 5
- WMKXFMUJRCEGRP-SRVKXCTJSA-N His-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N WMKXFMUJRCEGRP-SRVKXCTJSA-N 0.000 description 5
- 108010065920 Insulin Lispro Proteins 0.000 description 5
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 5
- AUNMOHYWTAPQLA-XUXIUFHCSA-N Leu-Met-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AUNMOHYWTAPQLA-XUXIUFHCSA-N 0.000 description 5
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 5
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 5
- XNKDCYABMBBEKN-IUCAKERBSA-N Lys-Gly-Gln Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O XNKDCYABMBBEKN-IUCAKERBSA-N 0.000 description 5
- WQDKIVRHTQYJSN-DCAQKATOSA-N Lys-Ser-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WQDKIVRHTQYJSN-DCAQKATOSA-N 0.000 description 5
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 5
- DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 5
- CDNPIRSCAFMMBE-SRVKXCTJSA-N Phe-Asn-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CDNPIRSCAFMMBE-SRVKXCTJSA-N 0.000 description 5
- MSHZERMPZKCODG-ACRUOGEOSA-N Phe-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MSHZERMPZKCODG-ACRUOGEOSA-N 0.000 description 5
- IIEOLPMQYRBZCN-SRVKXCTJSA-N Phe-Ser-Cys Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O IIEOLPMQYRBZCN-SRVKXCTJSA-N 0.000 description 5
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 5
- ZLXKLMHAMDENIO-DCAQKATOSA-N Pro-Lys-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLXKLMHAMDENIO-DCAQKATOSA-N 0.000 description 5
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 description 5
- KBUAPZAZPWNYSW-SRVKXCTJSA-N Pro-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KBUAPZAZPWNYSW-SRVKXCTJSA-N 0.000 description 5
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 5
- SEZGGSHLMROBFX-CIUDSAMLSA-N Pro-Ser-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O SEZGGSHLMROBFX-CIUDSAMLSA-N 0.000 description 5
- PRKWBYCXBBSLSK-GUBZILKMSA-N Pro-Ser-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O PRKWBYCXBBSLSK-GUBZILKMSA-N 0.000 description 5
- OYEDZGNMSBZCIM-XGEHTFHBSA-N Ser-Arg-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OYEDZGNMSBZCIM-XGEHTFHBSA-N 0.000 description 5
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 5
- ZOHGLPQGEHSLPD-FXQIFTODSA-N Ser-Gln-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZOHGLPQGEHSLPD-FXQIFTODSA-N 0.000 description 5
- DJACUBDEDBZKLQ-KBIXCLLPSA-N Ser-Ile-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O DJACUBDEDBZKLQ-KBIXCLLPSA-N 0.000 description 5
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 5
- ASJDFGOPDCVXTG-KATARQTJSA-N Thr-Cys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O ASJDFGOPDCVXTG-KATARQTJSA-N 0.000 description 5
- DSLHSTIUAPKERR-XGEHTFHBSA-N Thr-Cys-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O DSLHSTIUAPKERR-XGEHTFHBSA-N 0.000 description 5
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 description 5
- BDGBHYCAZJPLHX-HJGDQZAQSA-N Thr-Lys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BDGBHYCAZJPLHX-HJGDQZAQSA-N 0.000 description 5
- BEZTUFWTPVOROW-KJEVXHAQSA-N Thr-Tyr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O BEZTUFWTPVOROW-KJEVXHAQSA-N 0.000 description 5
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 5
- VTHNLRXALGUDBS-BPUTZDHNSA-N Trp-Gln-Glu Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N VTHNLRXALGUDBS-BPUTZDHNSA-N 0.000 description 5
- SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 description 5
- RIVVDNTUSRVTQT-IRIUXVKKSA-N Tyr-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O RIVVDNTUSRVTQT-IRIUXVKKSA-N 0.000 description 5
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 5
- JXGWQYWDUOWQHA-DZKIICNBSA-N Val-Gln-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N JXGWQYWDUOWQHA-DZKIICNBSA-N 0.000 description 5
- RKIGNDAHUOOIMJ-BQFCYCMXSA-N Val-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 RKIGNDAHUOOIMJ-BQFCYCMXSA-N 0.000 description 5
- SBJCTAZFSZXWSR-AVGNSLFASA-N Val-Met-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N SBJCTAZFSZXWSR-AVGNSLFASA-N 0.000 description 5
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 5
- ZLNYBMWGPOKSLW-LSJOCFKGSA-N Val-Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLNYBMWGPOKSLW-LSJOCFKGSA-N 0.000 description 5
- 108010092854 aspartyllysine Proteins 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000013599 cloning vector Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 108010064235 lysylglycine Proteins 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 108010070643 prolylglutamic acid Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108010080629 tryptophan-leucine Proteins 0.000 description 5
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 4
- DPLFNLDACGGBAK-KKUMJFAQSA-N Arg-Phe-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N DPLFNLDACGGBAK-KKUMJFAQSA-N 0.000 description 4
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 4
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 4
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 4
- FYVHHKMHFPMBBG-GUBZILKMSA-N His-Gln-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N FYVHHKMHFPMBBG-GUBZILKMSA-N 0.000 description 4
- 101000788682 Homo sapiens GATA-type zinc finger protein 1 Proteins 0.000 description 4
- 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- JTKGCYOOJLUETJ-ULQDDVLXSA-N Phe-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 JTKGCYOOJLUETJ-ULQDDVLXSA-N 0.000 description 4
- 241000235648 Pichia Species 0.000 description 4
- 241000311088 Schwanniomyces Species 0.000 description 4
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 4
- QQWNRERCGGZOKG-WEDXCCLWSA-N Thr-Gly-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O QQWNRERCGGZOKG-WEDXCCLWSA-N 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000001513 hot isostatic pressing Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 3
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 3
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 3
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 3
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- YYPFZVIXAVDHIK-IUCAKERBSA-N Gly-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN YYPFZVIXAVDHIK-IUCAKERBSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241000235649 Kluyveromyces Species 0.000 description 3
- 244000285963 Kluyveromyces fragilis Species 0.000 description 3
- 108010019598 Liraglutide Proteins 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 108020001096 dihydrofolate reductase Proteins 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 108010034529 leucyl-lysine Proteins 0.000 description 3
- 229960002701 liraglutide Drugs 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- RRBGTUQJDFBWNN-MUGJNUQGSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2,6-diaminohexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O RRBGTUQJDFBWNN-MUGJNUQGSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 241000351920 Aspergillus nidulans Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- 238000010156 Dunnett's T3 test Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 2
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 2
- 102000030595 Glucokinase Human genes 0.000 description 2
- 108010021582 Glucokinase Proteins 0.000 description 2
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 2
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 2
- 241001149669 Hanseniaspora Species 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- YPWHUFAAMNHMGS-QSFUFRPTSA-N Ile-Ala-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N YPWHUFAAMNHMGS-QSFUFRPTSA-N 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 2
- 241001138401 Kluyveromyces lactis Species 0.000 description 2
- RBEATVHTWHTHTJ-KKUMJFAQSA-N Lys-Leu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O RBEATVHTWHTHTJ-KKUMJFAQSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000221960 Neurospora Species 0.000 description 2
- 241000221961 Neurospora crassa Species 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- OYQBFWWQSVIHBN-FHWLQOOXSA-N Phe-Glu-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O OYQBFWWQSVIHBN-FHWLQOOXSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 241000223252 Rhodotorula Species 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000013262 cAMP assay Methods 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical group 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical group CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical group 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000000859 incretin Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000002473 insulinotropic effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000003509 long acting drug Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 108010084572 phenylalanyl-valine Proteins 0.000 description 2
- 108010083476 phenylalanyltryptophan Proteins 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 101150108727 trpl gene Proteins 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 1
- CEOOTQDKDICVJW-QNGWXLTQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-(tritylamino)hexanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CCCNC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 CEOOTQDKDICVJW-QNGWXLTQSA-N 0.000 description 1
- DVBUCBXGDWWXNY-SFHVURJKSA-N (2s)-5-(diaminomethylideneamino)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C3=CC=CC=C3C2=C1 DVBUCBXGDWWXNY-SFHVURJKSA-N 0.000 description 1
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- NGJOFQZEYQGZMB-KTKZVXAJSA-N (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NGJOFQZEYQGZMB-KTKZVXAJSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical class C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- OLVCTPPSXNRGKV-GUBZILKMSA-N Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OLVCTPPSXNRGKV-GUBZILKMSA-N 0.000 description 1
- 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
- 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
- 238000003276 AlphaScreen cAMP assay kit Methods 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000258957 Asteroidea Species 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 108010055448 CJC 1131 Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- SMEYEQDCCBHTEF-FXQIFTODSA-N Cys-Pro-Ala Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O SMEYEQDCCBHTEF-FXQIFTODSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- QMVCEWKHIUHTSD-GUBZILKMSA-N Gln-Met-Glu Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N QMVCEWKHIUHTSD-GUBZILKMSA-N 0.000 description 1
- CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 description 1
- 102400000324 Glucagon-like peptide 1(7-37) Human genes 0.000 description 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 1
- POJJAZJHBGXEGM-YUMQZZPRSA-N Gly-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN POJJAZJHBGXEGM-YUMQZZPRSA-N 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- HAPWZEVRQYGLSG-IUCAKERBSA-N His-Gly-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O HAPWZEVRQYGLSG-IUCAKERBSA-N 0.000 description 1
- 101500028772 Homo sapiens Glucagon-like peptide 1(7-36) Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 description 1
- BKTXKJMNTSMJDQ-AVGNSLFASA-N Leu-His-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N BKTXKJMNTSMJDQ-AVGNSLFASA-N 0.000 description 1
- QLDHBYRUNQZIJQ-DKIMLUQUSA-N Leu-Ile-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QLDHBYRUNQZIJQ-DKIMLUQUSA-N 0.000 description 1
- KPYAOIVPJKPIOU-KKUMJFAQSA-N Leu-Lys-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O KPYAOIVPJKPIOU-KKUMJFAQSA-N 0.000 description 1
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 1
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- JACAKCWAOHKQBV-UWVGGRQHSA-N Met-Gly-Lys Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN JACAKCWAOHKQBV-UWVGGRQHSA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- KRYSMKKRRRWOCZ-QEWYBTABSA-N Phe-Ile-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O KRYSMKKRRRWOCZ-QEWYBTABSA-N 0.000 description 1
- AOKZOUGUMLBPSS-PMVMPFDFSA-N Phe-Trp-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O AOKZOUGUMLBPSS-PMVMPFDFSA-N 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920000361 Poly(styrene)-block-poly(ethylene glycol) Polymers 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 102000035554 Proglucagon Human genes 0.000 description 1
- 108010058003 Proglucagon Proteins 0.000 description 1
- 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 235000018368 Saccharomyces fragilis Nutrition 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- UYTYTDMCDBPDSC-URLPEUOOSA-N Thr-Ile-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N UYTYTDMCDBPDSC-URLPEUOOSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- RRVUOLRWIZXBRQ-IHPCNDPISA-N Trp-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N RRVUOLRWIZXBRQ-IHPCNDPISA-N 0.000 description 1
- WMBFONUKQXGLMU-WDSOQIARSA-N Trp-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N WMBFONUKQXGLMU-WDSOQIARSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- JYVKKBDANPZIAW-AVGNSLFASA-N Val-Arg-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N JYVKKBDANPZIAW-AVGNSLFASA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001651 autotrophic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940014641 bydureon Drugs 0.000 description 1
- 229940084891 byetta Drugs 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- AIWAEWBZDJARBJ-PXUUZXDZSA-N fz7co35x2s Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)CCN1C(C=CC1=O)=O)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 AIWAEWBZDJARBJ-PXUUZXDZSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 108010045383 histidyl-glycyl-glutamic acid Proteins 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229940031154 kluyveromyces marxianus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011342 resin composition Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- OHSJPLSEQNCRLW-UHFFFAOYSA-N triphenylmethyl radical Chemical compound C1=CC=CC=C1[C](C=1C=CC=CC=1)C1=CC=CC=C1 OHSJPLSEQNCRLW-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明通过对特定融合蛋白质在分子的GLP‑1部分和Fc部分进行多个位置的替换。其中Fc第11位的Ser、85位的Val、第86位的Val、第87位的Ser和第91位的Val进行了替换,末端Lys缺失,从而在很大程度上克服了施用GLP‑1‑Fc融合物相关的潜在免疫原性的问题,而且体内外活性实验结果还证明,本发明公开的GLP‑1类似物活性明显高于现有GLP‑1类似物。因此,所述的类似物可用于更好地预防、防治或减轻糖尿病和肥胖症和/或并发症。
Description
技术领域
本发明属于遗传工程技术领域,具体涉及一种GLP-1类似物融合蛋白质。
背景技术
糖尿病(diabetes mellitus,DM)是由于体内胰岛素分泌不足或合成受阻导致内分泌代谢紊乱而引起血糖升高的一种复杂的代谢性疾病,主要分为1型糖尿病(type1diabetes mellitus,T1DM)、2型糖尿病(type2 diabetes mellitus,T2DM)以及其他类型的糖尿病。据统计,2型糖尿病所占比例较大,约占糖尿病患者总数的90%以上,其发病期多在35-40岁以后,发病后期会出现较严重的并发症。目前,糖尿病的治疗主要集中在以降低血糖浓度,减少并发症的发生等为目的,治疗方法主要是药物治疗。治疗2型糖尿病的药物主要有磺酰脲类、双胍类、α葡萄糖激酶抑制剂、抗IL-1β抗体和肠促胰岛素类药物,其中肠促胰岛素类药物具有多方面降糖功能而作为新型糖尿病治疗药物备受关注,根据作用机制可分为二肽基肽酶IV(dipeptidylpeptidase 4,DPP-4)抑制剂和胰高血糖素样肽(glucagonlikepeptide-1,GLP-1)受体激动剂两类。研究表明,这两类药物除具有降血糖、极少导致低血糖、安全性和耐受性较好等优点外,还对消化、中枢神经、心血管等多系统发挥保护作用。
胰高血糖素类似肽(Glucagon-like peptide,GLP)是人体分泌的一种肠道激素,由胰高血糖素原分子经肠道蛋白水解酶裂解而成,产生二种胰高血糖素类似肽GLP-1和GLP-2。其中GLP-1有二种活性形成,即GLP-1(7-37)和GLP-1(7-36)酰胺形式,在体内具有相同的促进胰岛素分泌的作用,故又称促胰岛素分泌肽(Incretin或Insulinotropicpeptide)(NegarSadrzadeh et.al.,Pharmaceutical Sciences,Vol.96,1925-1954(2007))。
GLP-1(7-37):
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly GlnAla Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly。
GLP-1激动剂作为一类多肽药物,目前还只能注射给药,为了提高患者顺应性,缓释注射剂、非注射给药成为这一类药物研发的主要方向。通过结构修饰,掩盖DPP-Ⅳ酶位点,延长生物半衰期,是目前最主流的做法。这种结构修饰包括链接高分子蛋白和聚乙二醇修饰两种,一周一次的Abiglutide和Dulaglutide就属于典型的前一种,尽管已有多个聚乙二醇修饰蛋白或多肽药物上市,但聚乙二醇修饰GLP-1类似物起步较晚,仅索玛鲁肽进入三期临床。当然也有的公司通过制剂的手段,制成缓释微球,实现一周一次,典型的产品就是Bydureon。也有的公司直接避开了注射给药的弊端,开发植入、口服、透皮和吸入之类的产品,其中口服给药是最理想的给药途径,但是需要解决GLP-1类似物在肠胃中被胃酸、酶破坏和吸收问题,以提高生物利用度,降低个体差异,目前口服GLP-1类似物走在最前沿的公司为Oramed公司和Emisphere公司,其中诺和诺德的NN9924就是一种口服索玛鲁肽,国内方面,上海蓝星申报了艾塞那肽肠溶片。
Exendin-4:
His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu GluAla Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala ProPro Pro Ser。
Exendin-4是从蜥蜴唾液中分离出的GLP-1类似物,由39个氨基酸组成,其氨基酸序列与GLP家族中数个成员有序列的相似性,与人GLP-1有53%的同源性。因为N端第二位是Ala(GLP-1为Gly),所以不易被DPP-Ⅳ酶降解,而具有较长的半衰期和较强的生物活性。Exendin-4的化学合成品命名为Exenatide(商品名Byetta),由Amylin和Lilly公司于1995年开始联合研发,2005年4月获得FDA的批准上市。
人GLP-1(7~36)在体内的表达和活性受到严格的调控,当其N端的第二位Ala被二肽基肽酶(dipeptidyl peptidase,DPP)水解后,形成无活性的GLP-1(9~36),该代谢产物还是GLP-1R的体内天然拮抗剂。因此,天然人活性型GLP-1在体内的半衰期很短,其新陈代谢的速率为2min;加上在生理状态下,GLP-1主要通过肾脏排泄,限制了人源GLP-1的临床应用。非人源的人工合成Exenatide的第二位氨基酸Gly不同于人GLP-1的Ala,能有效抵抗二肽酰基肽酶的降解;Exenatide的C端的刚性(PSSGAPPPS)氨基酸序列,可增加多肽稳定性,Exenatide在体内的降血糖能力比GLP-1强1000倍左右。
Exenatide肽二级结构:Exenatide的N端为不规则卷曲,中间部分在同一侧面上相互交替排列带相反电荷侧链的氨基酸残基,通过盐桥或极性氢键形成螺旋,C端则为亲水的“Trp-Cage”。Exenatide与GLP-1受体的相互作用机理已研究的比较清楚。
一系列不同结构设计已经开发用于延长GLP-1类似物结构半衰期,提高生物活性。CN1384755A公开了新型Exendin激动剂制剂及其给药方法,公开了Exenatide的化合物结构和制备方法。CN102532303A公开了使用甲氧基聚乙二醇修饰Exenatide中赖氨酸的氨基或N末端组氨酸残基的氨基。CN101980725B公开了脂肪酸-PEG-Exenatide。CN105753963A公开了单点或多点位氨基酸突变的Exenatide类似物。CN102397558A公开了将Exenatide中某些氨基酸用半胱氨酸取代,并使用PEG或末端被甲基取代的PEG修饰。
丹麦的Novo Nordisk公司开发的酰胺化的GLP-1衍生物Liraglutide(T,DiabetesCare,2007,30:1608-1610),与天然的GLP-1相比34位Lys被Arg所替代,同时含有16个碳的脂肪酸侧链通过谷氨酰基连接到GLP-1的26位Lys上。Liraglutide可与血浆中白蛋白形成非共价连接的衍生物,保留了GLP-1的功能,拮抗DPP IV的降解,其半衰期延长到11-15小时,适合每天一次的给药方式(Elbrond B,Diabetes Care,2002,25:1398-1404)。正在开发的另一个GLP-1类似物CJC-1131中C末端37位赖氨酸经体外修饰后,可以与血浆中白蛋白中34位半胱氨酸残基形成共价连接,同样可以实现一天给药一次的目标(Kim,JG,Diabetes,2003,52:751-759)。由此可见,通过化学或基因工程手段,将GLP-1和exendin-4经突变(1个或几个氨基酸)、缺失或添加氨基酸于C末端的GLP-1类似物,可以较好地保留生物活性。
虽然在GLP-1类似物长效药物开发做了诸多努力,但是目前市场上的GLP-1类似物稳定性较差和药效较低,作为长效药物研发的结构和活性基础,GLP-1类似物的创新性改造和研究仍是一个非常重要的课题。
已经采取多种途径在保持生物学活性的同时延长GLP-1肽的清除半寿期或降低该肽从机体的清除。一条途径涉及将GLP-1肽与免疫球蛋白Fc部分融合。免疫球蛋白一般在体内具有长循环半寿期。例如,IgG分子在人体具有高达23天的半寿期。免疫球蛋白Fc部分是这种体内稳定性的部分原因。在保留GLP-1分子生物学活性的同时,GLP-1-Fc融合蛋白质具有由免疫球蛋白Fc部分提供的稳定性而保留GLP-1分子的生物活性的优点。
然而多种融合蛋白质长时期反复施用时的免疫原性问题还是普遍存在的。通常蛋白质,包括治疗性蛋白,都具有免疫原性,这部分是因为蛋白质通过抗原提呈细胞内吞和蛋白水解后产物肽结合到称为主要组织相容性复合体(MHC)的分子上然后这些分子把肽提呈给T细胞。抗原提呈细胞(APC)表面的抗原肽-MHC复合体刺激T细胞增殖,分化并释放细胞因子。同时,B-细胞分化和抗体产生被诱导,这可以进一步通过清除治疗性蛋白而限制治疗性蛋白的效用。这样,来源于治疗性蛋白的抗原肽能够引起一系列不想要的免疫应答。治疗性蛋白的效用由于抗体的中和而受限,而且因为T-细胞和B-细胞应答会在患者中引起炎性和变态反应,其诱导经常是有害的。
发明内容
本发明提供一种GLP-1类似物融合蛋白质,其包含GLP-1类似物治疗肽和免疫球蛋白Fc部分,所述GLP-1类似物融合蛋白质在Fc部分进行多个位置的替换,从而在很大程度上克服了施用Fc融合物存在的潜在免疫原性问题,提高了稳定性。所述融合蛋白质结合的GLP-1类似物可以是能够与Fc融合的一些治疗肽,比如艾塞那肽、利拉鲁肽,利司那肽、索玛鲁肽、Ideglira、阿必鲁肽、度拉糖肽、ITCA650、LAEx4、Lixilan等。
本发明还提供一种改进的GLP-1类似物,体内外活性实验结果证明,本发明所述GLP-1类似物活性明显高于现有GLP-1类似物。因此,本发明所述的类似物可用于更好地预防、防治或减轻糖尿病和肥胖症和/或并发症。
本发明的GLP-1类似物与免疫球蛋白Fc通过接头形成融合蛋白质,所述免疫球蛋白Fc部分是对人IgG4的Fc片段修饰所得,其序列编号SEQ ID NO:1,具体序列为:
Ala-Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Xaa11-Cys-Pro-Ala-Pro-
Glu-Phe-Leu-Gly-Gly-Pro-Ser-Val-Phe-Leu-Phe-Pro-Pro-Lys-Pro-
Lys-Asp-Thr-Leu-Met-Ile-Ser-Arg-Thr-Pro-Glu-Val-Thr-Cys-Val-
Val-Val-Asp-Val-Ser-Gln-Glu-Asp-Pro-Glu-Val-Gln-Phe-Asn-Trp-
Tyr-Val-Asp-Gly-Val-Glu-Val-His-Asn-Ala-Lys-Thr-Lys-Pro-Arg-
Glu-Glu-Gln-Phe-Asn-Ser-Thr-Tyr-Arg-Xaa85-Xaa86-Xaa87-Val-Leu-Thr-
Xaa91-Leu-His-Gln-Asp-Trp-Leu-Asn-Gly-Lys-Glu-Tyr-Lys-Cys-Lys-
Val-Ser-Asn-Lys-Gly-Leu-Pro-Ser-Ser-Ile-Glu-Lys-Thr-Ile-Ser-
Lys-Ala-Lys-Gly-Gln-Pro-Arg-Glu-Pro-Gln-Val-Tyr-Thr-Leu-Pro-
Pro-Ser-Gln-Glu-Glu-Met-Thr-Lys-Asn-Gln-Val-Ser-Leu-Thr-Cys-
Leu-Val-Lys-Gly-Phe-Tyr-Pro-Ser-Asp-Ile-Ala-Val-Glu-Trp-Glu-
Ser-Asn-Gly-Gln-Pro-Glu-Asn-Asn-Tyr-Lys-Thr-Thr-Pro-Pro-Val-
Leu-Asp-Ser-Asp-Gly-Ser-Phe-Phe-Leu-Tyr-Ser-Arg-Leu-Thr-Val-
Asp-Lys-Ser-Arg-Trp-Gln-Glu-Gly-Asn-Val-Phe-Ser-Cys-Ser-Val-
Met-His-Glu-Ala-Leu-His-Asn-His-Tyr-Thr-Gln-Lys-Ser-Leu-Ser-
Leu-Ser-Leu-Gly,
其中第11位的Ser、85位的Val、第86位的Val、第87位的Ser和第91位的Val进行了替换,末端Lys缺失,具体为:
11位的Xaa为Pro;
85位的Xaa为Ala或Phe;
86位的Xaa为Phe或Glu;
87位的Xaa为Glu、Phe或Leu;
91位的Xaa为Gly。
序列1简写为:
在一个优选实施方案中,优选为SEQ ID NO:2,即序列2:
11位替换为Pro;
85位的Xaa为Ala;
86位的Xaa为Phe;
87位的Xaa为Glu;
91位的Xaa为Gly。
序列2简写:
在一个优选实施方案中,优选为SEQ ID NO:3,即序列3:
11位替换为Pro;
85位的Xaa为Phe;
86位的Xaa为Glu;
87位的Xaa为Phe;
91位的Xaa为Gly。
序列3简写:
所述的融合蛋白质,其GLP-1类似物为治疗肽,GLP-1类似物的C末端甘氨酸残基通过肽接头与Fc部分的N末端丙氨酸残基融合,其中肽接头是SEQ ID NO:4的序列,具体为Gly-Ala-Ala-Ala-Ala-Lys-Ser-Ala-Ala-Ala-Ala-Ser。
肽接头还可以选自如下的序列:
a)Gly-Gly-Gly-Gly-Ser-Lys-Lys-Lys-Lys-Ser-Gly-Gly-Gly-Gly-Ser,如SEQID NO:5所示;
b)Gly-Ala-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser,如SEQ ID NO:6所示;
c)Gly-Gly-Gly-Gly-Ser-Lys-Lys-Lys-Lys--Ser-Gly-Gly-Gly-Gly-Ser-Lys-Lys-Lys-Lys-Ser-Gly-Gly-Gly-Gly-Ser,如SEQ ID NO:7所示;
d)Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser(SEQ IDNO:8)。
所述融合蛋白质,其中GLP-1类似物是对GLP-1(7-37)修饰后所得,为方便表述对其重新编号,将原7位His编号为1位,序列为如下的SEQ ID NO:9即序列9:
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Xaa-Leu-Val-Lys-Gly-Xaa-Xaa;
第25位Xaa为Trp或Phe或His;
第30位Xaa为Val或Glu或Ala;
第31位Xaa为Val-Val-Lys-Leu-Lys-NH2;Ala-Ala-Lys-Gly-Gly-Lys-NH2;Leu-Leu-Leu-Lys-Lys-NH2;Leu-Lys-Leu-Leu-Leu-Arg-NH2。
在一个优选实施方案中,优选SEQ ID NO:10,即序列10:
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Phe-Leu-Val-Lys-Gly-Ala-Leu-Lys-Leu-Leu-Leu-Arg-NH2。
在一个优选实施方案中,优选SEQ ID NO:11,即序列11:
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Phe-Leu-Val-Lys-Gly-Ala-Val-Val-Lys-Leu-Lys-NH2。
在一个优选实施方案中,优选SEQ ID NO:12,即序列12:
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Phe-Leu-Val-Lys-Gly-Glu-Leu-Lys-Leu-Leu-Leu-Arg-NH2。
在一个优选实施方案中,优选SEQ ID NO:13,即序列13:
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Phe-Leu-Val-Lys-Gly-Val-Leu-Lys-Leu-Leu-Leu-Arg-NH2。
在一个优选实施方案中,优选SEQ ID NO:14,即序列14:
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Phe-Leu-Val-Lys-Gly-Val-Leu-Leu-Leu-Lys-Lys-NH2。
在一个优选实施方案中,优选SEQ ID NO:15,即序列15:
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-His-Leu-Val-Lys-Gly-Ala-Leu-Lys-Leu-Leu-Leu-Arg-NH2。
在一个优选实施方案中,优选SEQ ID NO:16,即序列16:
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Ala-Val-Val-Lys-Leu-Lys-NH2。
在一个优选实施方案中,所述的融合蛋白质,其中GLP-1类似物的序列是SEQ IDNO:10。
所述的融合蛋白质为序列10-接头序列4-序列2,命名为HIP925-1,序列编号为SEQID NO:17具体蛋白序列为:
所述的融合蛋白质为序列10-接头序列4-序列3,命名为HIP925-2,序列编号为SEQID NO:18具体蛋白序列为:
在一个优选实施方案中,所述的融合蛋白质,其中GLP-1类似物的序列是SEQ IDNO:11。
所述的融合蛋白质为序列11-接头序列4-序列2,命名为HIP925-3,序列编号为SEQID NO:19具体蛋白序列为:
所述的融合蛋白质为序列11-接头序列4-序列3,命名为HIP925-4,序列编号为SEQID NO:20具体蛋白序列为:
在一个优选实施方案中,所述的融合蛋白质,其中GLP-1类似物的序列是SEQ IDNO:12。
所述的融合蛋白质为序列12-接头序列4-序列2,命名为HIP925-5,序列编号为SEQID NO:21具体蛋白序列为:
所述的融合蛋白质为序列12-接头序列4-序列3,命名为HIP925-6,序列编号为SEQID NO:22具体蛋白序列为:
在一个优选实施方案中,所述的融合蛋白质,其中GLP-1类似物的序列是SEQ IDNO:13。
所述的融合蛋白质为序列13-接头序列4-序列2,命名为HIP925-7,序列编号为SEQID NO:23具体蛋白序列为:
所述的融合蛋白质为序列13-接头序列4-序列3,命名为HIP925-8,序列编号为SEQID NO:24具体蛋白序列为:
在一个优选实施方案中,所述的融合蛋白质,其中GLP-1类似物的序列是SEQ IDNO:14。
所述的融合蛋白质为序列14-接头序列4-序列2,命名为HIP925-9,序列编号为SEQID NO:25具体蛋白序列为:
所述的融合蛋白质为序列14-接头序列4-序列3,命名为HIP925-10,序列编号为SEQ ID NO:26具体蛋白序列为:
在一个优选实施方案中,所述的融合蛋白质,其中GLP-1类似物的序列是SEQ IDNO:15。
所述的融合蛋白质为序列15-接头序列4-序列2,命名为HIP925-11,序列编号为SEQ ID NO:27具体蛋白序列为:
在一个优选实施方案中,所述的融合蛋白质,其中GLP-1类似物的序列是SEQ IDNO:16。
所述的融合蛋白质为序列16-接头序列4-序列2,命名为HIP925-12,序列编号为SEQ ID NO:28具体蛋白序列为:
上述序列中,与Fc融合前的Glp-1类似物序列10-16表现出比其他Glp-1类似物更优的稳定性,其中序列10和14更优;与Fc融合后能够进一步延长半衰期,其中Fc序列2优于序列3。
所述的融合蛋白质,其中GLP-1类似物还可以是艾塞那肽、利拉鲁肽,利司那肽、索玛鲁肽、Ideglira、阿必鲁肽、度拉糖肽、ITCA650、LAEx4、Lixilan等。
所述融合蛋白可以通过固相合成方法得到,也可以通过真核细胞表达得到,也可以两种方法结合。
固相合成法:
当C末端为羧基时,选择王树脂进行二种多肽的化学固相合成。合成结束后,将得到的侧链保护基的多肽树脂进行裂解,C末端从树脂上断裂下来形成羧基。当多肽C末端为酰胺,选择Fmoc-PAL-PEG-PS树脂进行多肽的化学固相合成。合成结束后,将得到的侧链保护基的多肽树脂进行裂解,C末端从树脂上断裂下来形成酰胺。以上固相合成是在多肽合成仪上进行。
首先将C末端的半胱氨酸连接树脂,然后一个一个的氨基酸从C端向N端进行。待合成结束后,脱保护基和从树脂上断裂后,用反向HPLC层析(Waters公司,C18制备柱)对Glp-1类似物多肽进行纯化。纯化条件为A相含0.5%(V/V)乙酸的水溶液,B相为含80%乙腈和0.5%(V/V)乙酸的水溶液,0-100%B液梯度洗脱。收集目的多肽,经冻干成干粉。经质谱分析,序列10的GLP-1的分子量为4542.06,与理论值一致。
在一个参考实施方案中,本发明所修饰的GLP-1类似物的制备方法如下:
第31位Xaa为Val-Val-Lys-Leu-Lys-NH2时:选择固相合成法,进一步地,采用Fmoc方法。由于多肽C端为酰胺基,对于Fmoc方法,可以使用的树脂为Fmoc-Rink树脂,其原理为利用Fmoc-Lys(Trt)-OH的羧基与载体氨基反应形成稳定的酰胺健,接完肽后可经裂解获得粗品。
第31位为Leu-Lys-Leu-Leu-Leu-Arg-NH2时,选择固相合成法,进一步地,采用Fmoc方法。由于多肽C端为酰胺基,对于Fmoc方法,可以使用的树脂为Fmoc-Rink树脂,其原理为利用Fmoc-Arg(Trt)-OH的羧基与载体氨基反应形成稳定的酰胺健,接完肽后可经裂解获得粗品。
选定以Fmoc-Rink树脂(100~200目,交联度为1-2%,取代值为0.3~0.6mmol NH/g)为起始原料,保护氨基酸与Fmoc-Rink树脂的摩尔比为2:1(或3:1)。取起始Fmoc-Rink树脂(取代值=0.436mmol/g),用20%哌啶(PIP/DMF)为去保护剂,室温反应25分钟,抽滤,用DMF(或DCM)洗涤树脂6次。取等摩尔量的保护氨基酸Fmoc-AAn和HOBt,用DMF溶解,置于-5℃的环境中冷却30分钟以上,另取N,N-二异丙基碳二亚胺的二氯甲烷溶液,慢慢加入至保护氨基酸DMF溶液中,于-5-5℃的环境中搅拌反应30分钟后加入到去保护的树脂中。
在去保护后的树脂与经活化的保护氨基酸反应3小时后,用茚三酮检测监控缩合反应的情况:缩合反应不完全时树脂为蓝色或深蓝色;缩合反应完全时树脂为无色或淡黄色。监测缩合完全缩合后,用DMF洗涤树脂6次。按多肽序列,依次进行活化氨基酸的缩合。完成接肽反应后,用DMF洗涤树脂再用甲醇收缩,减压干燥树脂。
按13mL/g肽树脂用量,将干燥的肽树脂加入到TFA裂解试剂(以ml:ml:ml:g计,TFA:H2O:TIS:DTT=90:2.5:2.5:5),0-5℃反应反应30min后,室温搅拌反应2-3h。反应混合物过滤,收集滤液,35℃减压浓缩至初始体积的25%。将浓缩液加到在-10℃以下冷冻的无水乙醚中,摇匀后在-10℃以下沉淀60分钟,过滤收集滤饼,再用无水乙醚洗涤滤饼3-5次,滤饼减压干燥至恒重,得多肽粗品。
取多肽粗品,用10%醋酸水溶液溶解,备纯化用。使用高效液相制备色谱纯化,流动相系统为0.1%TFA/水溶液-0.1%TFA/乙腈溶液。纯化用色谱填料为10μm的反相C18,紫外检测波长为215nm,50mm*300mm的色谱柱,流速为60mL/min,每次进样2.0-3.0g,采用梯度系统洗脱,循环进样纯化,收集主峰并用分析液相检测纯度,纯化主峰纯度应大于98%。制备洗脱液在30℃-37℃水浴条件下减压浓缩,得到一次纯化物料浓缩液。
将一次纯化收集到的物料浓缩液进行二次除盐纯化,条件为:流动相A相:纯化水;B相:乙腈溶液,检测波长:215nm,流速为30~60ml·min-1。收集目标馏分,将收集到的馏分于水温低于35℃减压浓缩至馏分不再流出,将剩余馏分冻干,得到精制品,并真空冷冻干燥,得到GLP-1类似物的纯品。
细胞表达方法可以参照CN 104277112 A,首先构建融合蛋白质的编码基因;然后将所述基因克隆到真核表达载体,得到可表达所述融合蛋白的真核表达载体;再用所述表达载体转染宿主细胞,使其表达所述重组融合蛋白,然后分离纯化即得。真核表达载体可以为PET32等。所用宿主细胞可以为FreeStyle 293F、酵母细胞、CHO细胞、NSO细胞等。
其中,野生型人类IgG4蛋白质可以从多种来源获得。例如,可以从以可检测水平表达目的mRNA的细胞制备cDNA文库以获得这些蛋白质。使用特定目的蛋白质的公开的DNA或蛋白质序列设计的探针可以对文库进行筛选。例如,在Adams等人,(1980)Biochemistry19:2711-2719;Goughet等人,(1980)Biochemistry 19:2702-2710;Dolby等人,(1980)Proc.Natl.Acad.Sci.USA 77:6027-6031;Rice等人,(1982)Proc.Natl.Acad.Sci.USA79:7862-7862;Falkner等人,(1982)Nature 298:286-288;以及Morrison等人,(1984)Ann.Rev.Immunol.2:239-256中描述了免疫球蛋白轻或重链恒定区。
可以使用标准程序以所选探针筛选cDNA或基因组文库,例如在Sambrook等人,《Molecular Cloning:A Laboratory Manual》,Cold SpringHarbor Laboratory Press,NY(1989)中所述。分离编码免疫球蛋白蛋白质的基因的备选方法是使用PCR方法[Sambrook等人,如上;Dieffenbach等人,《PCR Primer:A Laboratory Manual》,Cold SpringHarborLaboratory Press,NY(1995)]。可以基于已发表的序列设计PCR引物。
从特定文库克隆的全长野生型序列通常可以作为产生本发明IgG4 Fc类似物片段的模板,其中IgG4 Fc类似物片段保留了赋予GLP-1类似物较长血浆半寿期的能力,GLP-1类似物是融合蛋白质的一部分。可以使用PCR技术,用经设计与对应于IgG4 Fc类似物片段所需末端的序列杂交的引物产生该片段。也可以设计PCR引物产生限制性酶位点以便于克隆到表达载体中。
可以通过多种不同的方法产生编码本发明的GLP-1类似物的DNA,所述方法包括如上所述的那些克隆方法和化学合成的DNA。
融合蛋白序列编号SEQ ID NO:17是序列SEQ ID NO:2通过肽接头SEQ ID NO:4与SEQ ID NO:10连接所得融合蛋白质,其优选地多核苷酸序列编号为SEQ ID NO:29,序列为:
在一个优选实施方案中,本发明采用的信号肽氨基酸序列如SEQ ID NO:30所示,具体序列如下:
MGKLIFWLVF WLTIFWLGSA 20。
所述信号肽的多核苷酸序列如SEQ ID NO:31所示,具体序列如下:
ATGGGCAAAC TCATATTCTG GCTTGTGTTT TGGCTGACTA TTTTTTGGCT TGGATCAGCT 60。
以此处所述用于融合蛋白质产生的表达或克隆载体转染或转化宿主细胞,并在经改良适于诱导启动子、选择转化子或扩增编码所希望的序列的基因的常规营养培养基中培养。技术人员不用过多实验方法即可以选择例如培养基、温度、pH等培养条件。一般而言,可以在《Mammalian CellBiotechnology:APractical Approach》,M.Butler编(IRL Press,1991)和如上之Sambrook等人著作中找到将细胞培养生产力最大化的原理、方法和实践技术。普通技术人员已知转染方法,例如CaPO4和电穿孔。在美国专利号4,399,216中描述了哺乳动物细胞宿主系统转化的一般方面。通常根据van Solingen等人,J Bact.130(2):946-7(1977)和Hsiao等人,Proc.Natl.Acad.Sci.USA 76(8):3829-33(1979)的方法进行酵母转化。然而,也可以使用将DNA引入细胞的其他方法,例如核微注射、电穿孔、细菌与完整细胞的原生质体融合、或聚阳离子,例如1,5-二甲基-1,5-二氮十一亚甲基聚甲溴化物(polybrene)或polyomithine。关于转化哺乳动物细胞的多种技术,见Keown等人,Methodsin Enzymology 185:527-37(1990)和Mansour等人,Nature 336(6197):348-52(1988)。
克隆或表达此处载体中核酸(例如DNA)的合适的宿主细胞包括FreeStyle 293F、酵母细胞、CHO细胞、NSO细胞等。
真核微生物例如丝状真菌或酵母是融合蛋白质载体的合适的克隆或表达宿主。酿酒酵母(Saccharomyces cerevisiae)是常用的低等真核宿主微生物。其他包括粟酒裂殖酵母(Schizosaccharomyces pombe)[Beach和Nurse,Nature 290:140-3(1981);1995年5月2日公布的EP 139,383];Muyveromyces宿主[美国专利号4,943,529;Fleer等人,Bio/Technology9(10):968-75(1991)]例如乳酸克鲁维酵母(K.lactis)(MW98-8C、CBS683、CBS4574)[de Louvencourt等人,J.Bacteriol.154(2):737-42(1983)];脆壁克鲁维酵母(K.fiagilis)(ATCC 12,424)、保加利亚克鲁维酵母(K.bulgaricus)(ATCC 16,045)、威克克鲁维酵母(K wickeramii)(ATCC24,178)、K waltii(ATCC 56,500)、果蝇克鲁维酵母(K.drosophilarum)(ATCC 36.906)[Van den Berg等人,Bio/Technology 8(2):135-9(1990)];K.thermotoierans和马克斯克鲁维酵母(K.marxianus);yarrowia(EP402,226);巴斯德毕赤酵母(Pichia pastoris)(EP 183,070)[Sreekrishna等人,J.BasicMicrobiol.28(4):265-78(1988)];假丝酵母属(Candida);Trichoderma reesia(EP 244,234);粗糙脉孢霉(Neurospora crassa)[Case等人,Proc.Natl.Acad Sci.USA76(10):5259-63(1979)];许旺酵母属(Schwanniomyces),例如许旺酵母(Schwanniomycesoccidentulis)(EP394,538,1990年10月31日发表);以及丝状真菌例如脉孢霉属(Neurospora)、青霉属(Penicillium)、Tolypocladium(WO 91/00357,1991年1月10日发表)以及曲霉属(Aspergillus)宿主,例如构巢曲霉(A.nidulans)[Balance等人,Biochem.Biophys.Res.Comm.112(1):284-9(1983)];Tilburn等人,Gene 26(2-3):205-21(1983);Yelton等人,Proc.Natl.Acad.Sci.USA 81(5):1470-4(1984)]和黑曲菌(A.niger)[Kelly和Hynes,EMBO J.4(2):475-9(1985)]。甲基营养酵母选自汉逊酵母属(Hansenula)、假丝酵母属(Candida)、克勒克酵母属(Kloeckera)、毕赤酵母属(Pichia)、酵母属、球拟酵母属(Torulopsis)和红酵母属(Rhodotorula)。可以在C.Antony,《The Biochemistry ofMethylotrophs》,269(1982)中找到这类酵母示范性的特定种的名单。
表达本发明融合蛋白质的合适的宿主细胞来自多细胞生物。无脊椎动物细胞的实例包括昆虫细胞,例如果蝇S2和灰赤夜蛾(Spodoptera)Sp、灰赤夜蛾high5及植物细胞。有用的哺乳动物宿主细胞系的实例包括NSO骨髓瘤细胞、中国仓鼠卵巢(CHO)细胞、SP2和COS细胞。更特定的实例包括以SV40转化的猴肾脏CVl系(COS-7,ATCC CRL 1651);人胚胎肾系[293或在悬浮培养中生长的亚克隆293细胞,Graham等人,J.Gen Virol.,36(1):59-74(1977)];中国仓鼠卵巢细胞/-DHFR[CHO,Urlaub和Chasin,Proc.Natl.Acad.Sci.USA,77(7):4216-20(1980)];小鼠支持细胞[TM4,Mather,Biol.Reprod.23(1):243-52(1980)];人类肺细胞(W138.ATCCCCL 75);人类肝细胞(Hep G2、HB 8065);以及小鼠乳腺肿瘤(MMT060562,ATCC CCL51)。
表达和克隆载体都含有使载体能够在一种或多种所选宿主细胞中复制的核酸序列。表达和克隆载体一般将含有选择基因,也称为选择标记。典型的选择基因编码(a)赋予抗生素或其他毒素(例如新霉素、氨甲蝶呤或四环素)抗性、(b)弥补自养缺陷、或(c)补充不能从复杂培养基获得的关键营养物(例如编码芽孢杆菌D-丙氨酸消旋酶的基因)的蛋白质。
哺乳动物细胞合适的选择标记的实例是能够鉴定有能力吸收融合蛋白质编码核酸的细胞的那些选择标记,例如DHFR或胸苷激酶。当使用野生型DHFR时,恰当的宿主细胞是如[Urlaub和Chasin,Proc.Natl.Acad.Sci.USA,77(7):4216-20(1980)]所描述的制备并增殖的DHFR活性缺陷的CHO细胞系。在酵母中使用的合适的选择基因是存在于酵母质粒YRp7中的trpl基因[Stinchcomb等人,Nature 282(5734):39-43(1979);Kingsman等人,Gene 7(2):141-52(1979);Tschumper等人,Gene 10(2):157-66(1980)]。Trpl基因为缺乏在色氨酸中生长的能力的酵母突变株例如ATCCNo.44076或PEPC1提供选择标记[Jones,Genetics85:23-33(1977)]。
表达和克隆载体通常含有与融合蛋白质编码核酸序列有效连接以指导mRNA合成的启动子。由多种可能的宿主细胞识别的启动子广为人知。与酵母宿主使用的合适的启动子序列实例包括3-磷酸甘油酸激酶[Hitzeman等人,J.Biol.Chem.255(24):12073-80(1980)]或其他糖酵解酶[Hess等人,J.Adv.Enzyme Reg.7:149(1968);Holland,Biochemistry 17(23):4900-7(1978)],例如烯醇酶、甘油醛-3-磷酸脱氢酶、己糖激酶、丙酮酸脱羧酶、磷酸果糖激酶、葡萄糖-6-磷酸异构酶、3-磷酸甘油酸变位酶、丙酮酸激酶、丙糖磷酸异构酶、磷酸葡萄糖异构酶和葡糖激酶。其他酵母启动子是醇脱氢酶2、异细胞色素C、酸性磷酸酶、与氮素代谢有关的降解酶、金属硫蛋白、3-磷酸甘油醛脱氢酶和负责麦芽糖和半乳糖利用的酶的启动子区,所述启动子是可诱导的启动子,具有由生长条件控制转录的额外的优点。在EP 73,657中进一步描述了用于酵母表达的合适的载体和启动子。例如,通过启动子可以控制融合蛋白质编码mRNA从哺乳动物宿主细胞中载体的转录,所述启动子可以来自病毒基因组,例如多瘤病毒、禽痘病毒、腺病毒(例如腺病毒2)、牛乳头瘤病毒、鸟肉瘤病毒、巨细胞病毒、逆转录病毒、乙型肝炎病毒和猿病毒40(SV 40);异源哺乳动物启动子,例如肌动蛋白启动子或免疫球蛋白启动子,以及热休克启动子,条件是这些启动子与宿主细胞系统相容。
可以通过向载体中插入增强子序列增加高等真核细胞对编码融合蛋白质的多核苷酸的转录。增强子是作用于启动子以增加其转录的DNA顺式作用元件,通常约10至300bp。已知许多来自哺乳动物基因(珠蛋白、弹性蛋白酶、白蛋白、a-酮蛋白(ketoprotein)和胰岛素)的增强子序列。然而,人们一般将使用真核细胞病毒启动子。实例包括复制起点后侧的SV40增强子(bp 100-270)、巨细胞病毒早期启动子增强子、复制起点后侧的多瘤病毒增强子、以及腺病毒增强子。可以将增强子在融合蛋白质编码序列的5′或3′位剪接在载体中,但是优选位于启动子5′位。
用于真核宿主细胞(酵母、真菌、昆虫、植物、动物、人类或其他多细胞生物的有核细胞)的表达载体也将含有转录终止和稳定mRNA所必需的序列。通常可以从真核或病毒DNA或cDNA的5′以及偶然从3′非翻译区获得这些序列。这些区域含有转录为编码融合蛋白质的mRNA中非翻译部分中聚腺苷酸化片段的核苷酸片段。
可以从培养基或宿主细胞裂解物中回收多种形式的融合蛋白质。如果是膜结合的,可以使用合适的去污剂溶液(例如Triton-X 100)或酶切割将其从膜上释放。可以通过多种物理或化学方法(例如循环冻融、超声处理、机械破碎或细胞裂解试剂)来破碎融合蛋白质表达中使用的细胞。
一旦在合适的宿主细胞中表达本发明的融合蛋白质,就可以分离并纯化类似物。下列步骤是适宜的纯化步骤的代表:羧甲基纤维素分级分离;凝胶过滤例如Sephadex G-75;阴离子交换树脂例如DEAE或Mono-Q;阳离子交换例如CM或Mono-S;金属鳌合柱以结合多肽的表位标签形式;反相HPLC;层析聚焦;硅胶;乙醇沉淀;以及硫酸铵沉淀。
可以使用多种蛋白质纯化方法,这类方法为本领域所公知并在例如Deutscher,Methods in Enzymology 182:83-9(1990)和《Scopes,ProteinPurification:Principlesand Practice》,Springer-Verlag,NY(1982)中得到描述。所选的纯化步骤取决于使用的生产方法以及产生的特定融合蛋白质的性质。例如,使用蛋白质A或蛋白质G亲合基质可以有效纯化包含Fc片段的融合蛋白质。可以使用低或高pH缓冲液从亲合基质洗脱融合蛋白质。温和的洗脱条件将有助于防止融合蛋白质的不可逆变性。
Fc部分包含第11、85、86、87、91位的替换,末端lys缺失。替换后的类似物降低了融合蛋白质的免疫原性。
本发明的融合蛋白质含有来自人类IgG4,但是与野生型人类序列相比包括多个替换的Fc部分。Fc部分由通过非共价相互作用和二硫键结合的抗体的两个重链恒定区组成。Fc部分可以包含铰链区,并经CH2和CH3结构域延伸到抗体C末端。Fc部分还可以包含一个或多个糖基化位点。
天然Glp-1(7-37):
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly
本发明融合蛋白质的GLP-1类似物部分与天然Glp-1(7-37)相比包含原第31、36、37位的替换(即本发明新编码序列第25、30和31位的替换)。
本发明所述的GLP-1类似物可采用Fmoc法人工化学合成,其C末端被酰胺化。
本发明的GLP-1类似物可以成盐,包括多种无机或有机盐,如盐酸盐、磷酸盐、硫酸盐、马来酸盐、草酸盐、柠檬酸盐和乳酸盐;与某些无机、有机碱成盐,如氢氧化钠和N-甲基-葡萄糖胺成盐。
本发明所述GLP-1类似物可以以单一药物形式给药或可以与其它药物联合给药,或作为药学上可接受的载体,或为长效多肽药物开发提供可修饰的活性前体。其应用可以使用GLP-1类似物或其可药用盐及药学上可接受的载体。“药学上可接受的载体”不会破坏本发明的化合物和其可用盐的药学活性,同时其有效用量对人体无毒。“药学上可接受的载体”可使用但不限于:离子交换材料、硬脂酸铝、卵磷脂、药物制剂用血清蛋白、饱和植物脂肪酸、纤维素物质、乙烯-聚氧乙烯-嵌段聚合物、环糊精或其经化学修饰的衍生物或其他可溶性衍生物等。
其他可药用辅料如填充剂如无水乳糖、淀粉、乳糖珠粒和葡萄糖,粘合剂如微晶纤维素、崩解剂如交联羧甲基纤维素钠、交联羧甲基淀粉、低取代羟丙基纤维素,润滑剂如硬脂酸镁,吸收促进剂、赋形剂、增溶剂和着色剂等也可加入本发明的药物组合物中。
上述本发明的GLP-1类似物或其可药用盐以及药物组合物可通过肠道或者非肠道途径给药。非肠道给药途径包括皮下、皮内、肌内、经鼻、粘膜给药或吸入。制剂可开发注射剂、霜剂、软膏剂、贴剂和气雾剂等。
本发明的GLP-1类似物或其融合蛋白或其可药用盐以及药物组合物可用于相关疾病的单一用药或联合用药治疗,为本领域技术人员能够理解的范围。
本发明所述融合蛋白质可以用于生产治疗非胰岛素依赖性糖尿病的药物,也可以用于生产在超重受试者中治疗肥胖或诱导体重减轻的药物。
本发明提供了一些术语的解释以便于更好地理解本发明技术方案。
“多肽”是由天然产生或合成的肽键连接的氨基酸残基的聚合物。少于大约10个氨基酸残基的多肽通常被称为“肽”。
“Fc”区含有包含抗体的CH2和CH3结构域的两个重链片段。两个重链片段由两个或多个二硫键并通过CH3结构域的疏水作用保持在一起。
“蛋白质”是包括一个或多个多肽链的大分子。蛋白质也可以包含非肽的成分,如碳水化合物基团。可以在生产蛋白质的细胞中将碳水化合物和其它非肽取代基团加入到蛋白质中,并且该基团将因细胞的类型不同而不同。本文给蛋白质下定义是依据它们的氨基酸主链结构;对象碳水化合物基团之类的取代基一般不作规定,但其仍然可以存在。
“异源肽”用非宿主DNA分子编码的肽或多肽是“异源”肽或多肽。
“克隆载体”是一种在宿主细胞中具有自我复制能力的核酸分子,例如质粒、粘粒或噬菌体。克隆载体一般含有一个或少量允许在不丧失载体基本生物功能的情况下可以以特定方式插入核酸分子的限制性核酸内切酶识别位点,以及编码适合供克隆载体转化细胞的鉴定和选择之用的标记基因的核苷酸序列。标记基因一般包括提供四环素抗性或氨苄青霉素抗性的基因。克隆载体都有一个松弛的复制子,能带动外源基因,在宿主细胞中复制扩增,它是用来克隆和扩增DNA片段(基因)的载体。
“表达载体”具有克隆载体的基本元件(ori,Ampr,Mcs等)还具有转录/翻译所必需的DNA顺序的载体;是一些用于工程生产的细菌,被导入的目标基因会在此类细菌中得到表达,生产出我们需要的产物,导入的基因是由克隆载体产出的,表达载体具有较高的蛋白质表达效率,一般因为具有强的启动子。
“重组宿主”是一种含有异源核酸分子,如克隆载体或表达载体的细胞。
“整合的转化体”是重组宿主细胞,在其中异源DNA被整合进入到细胞的基因组DNA中。
“融合蛋白质”是由包含至少两个基因的核苷酸序列的核酸分子表达的杂合蛋白质。
“免疫球蛋白部分”是指包含免疫球蛋白恒定区的多肽。例如:免疫球蛋白部分可以包含重链恒定区。
“表达”是指基因产物的生物合成。例如,就结构基因而论,表达包括将结构基因转录到mRNA中和将mRNA翻译为一个或多个多肽。
具体实施方式
以下通过实施例对本发明进行更加详细的说明。根据本发明的要旨,这些实施例仅用于更加具体地说明本发明,不意味着限制本发明的范围,这对于本发明所属技术领域的技术人员而言显而易见。实施例以HIP925-1~12为例进行例证。所用材料中未特殊说明的均为市售可得。
本发明中一些常见缩写具有以下含义:
缩写 | 含义 |
Resin | 树脂 |
Fmoc | 芴甲氧羰基 |
HOBt | 1-羟基苯并三唑 |
DCM | 二氯甲烷 |
DMF | N,N-二甲基甲酰胺 |
DIC | N,N'-二异丙基碳二亚胺 |
Rink Amide-MBHA Resin | Rink酰胺-MBHA |
MeOH | 甲醇 |
TFA | 三氟乙酸 |
TIS | 三异丙基硅烷 |
DTT | 二硫苏糖醇 |
-Trt | 三苯甲基 |
-tBu | 叔丁基 |
-Pbf | 2,2,4,6,7-五甲基苯并呋喃-5-磺酰基 |
-Boc | 叔丁氧羰基 |
-OtBu | 叔丁酯基 |
参考实施例1.序列10的制备
序列10:分子量3910.45;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Phe-Leu-Val-Lys-Gly-Ala-Leu-Lys-Leu-Leu-Leu-Arg-NH2。
本实施例提供序列10多肽的制备方法。
序列10多肽的制备方法:采用提供Fmoc保护的氨基树脂,脱除氨基树脂上的Fmoc保护基后,合成序列10多肽肽树脂,脱除树脂及侧链保护基获得序列10多肽粗品,序列10多肽粗品经制备纯化得序列10多肽精制品。
(1)序列10多肽肽树脂的制备:
在100ml的固相反应器中加入Rink Amide-MBHA Resin树脂(5.0g,0.42mmol/g,2.1mmol)及40ml CH2Cl2,将树脂溶胀30min,抽除CH2Cl2,用30ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,再次用30ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,采用DMF(6×40ml)洗涤树脂,备用;同时将4.1g Fmoc-Arg(pbf)-OH(6.3mmol)和0.9g HOBt(6.6mmol)置于100ml烧瓶中,加入40ml DMF溶解,冰浴降温至0~5℃,滴加1.0ml DIC(6.6mmol),加完后反应5min,将该反应液转移至上述所得脱除Fmoc的氨基树脂中,N2鼓泡混匀,缩合反应3h后,抽除反应液,用DMF(6×40ml)洗涤树脂。
重复上述脱保护及缩合步骤,采用逐一偶联的方式,继续依次偶联Fmoc-Leu-OH、Fmoc-Leu-OH、Fmoc-Leu-OH、Fmoc-Lys(Boc)-OH、Fmoc-Leu-OH、Fmoc-Ala-OH、Fmoc-Gly-OH、Fmoc-Lys(Boc)-OH、Fmoc-Val-OH、Fmoc-Leu-OH、Fmoc-Phe-OH、Fmoc-Ala-OH、Fmoc-Ile-OH、Fmoc-Phe-OH、Fmoc-Glu(Otbu)-OH、Fmoc-Lys(Boc)-OH、Fmoc-Ala-OH、Fmoc-Ala-OH、Fmoc-Gln(Trt)-OH、Fmoc-Gly-OH、Fmoc-Glu(Otbu)-OH、Fmoc-Leu-OH、Fmoc-Tyr(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Val-OH、Fmoc-Asp(Otbu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Thr(tBu)-OH、Fmoc-Phe-OH、Fmoc-Thr(tBu)-OH、Fmoc-Gly-OH、Fmoc-Glu(Otbu)-OH、、Fmoc-Ala-OH、Fmoc-His(Trt)-OH直至完成氨基树脂负载的序列10多肽肽树脂的合成,其中脱保护与缩合的步骤基本相同。合成完毕,用DMF(6×40ml)洗涤树脂,向固相反应器中加入40ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,再次用40ml20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,采用DMF(4×40ml)洗涤树脂,再用MeOH(2×40ml)洗涤树脂,35℃真空烘干燥肽树脂。
(2)序列10多肽粗品的制备:
将以上制得的氨基树脂负载的序列10多肽肽树脂加入150ml TFA/TIS/H2O(v/v/v=95:2.5:2.5)混合溶液脱除树脂和侧链保护基,2.5h后抽滤,收集滤液,再用TFA/TIS/H2O(体积比为95:2.5:2.5)混合溶液(10ml)洗涤树脂,抽滤,合并滤液,35℃以下,减压浓缩至馏分不再流出,将浓缩液缓慢倒入3L冷乙醚中,搅拌,析出白色沉淀,过滤,滤饼碾碎,再用冷乙醚洗涤3次,35℃真空干燥5小时,得序列10多肽粗品7.3g,收率:89.0%,HPLC纯度:53.2%。
(3)序列10多肽精制品的制备:
将7.3g序列10多肽粗品溶于20ml 10%醋酸水溶液中,0.45μm膜过滤,用制备型HPLC纯化:选用C18柱子上样,每次上样1.8~2.2g,波长214nm,(10%乙腈—H2O(含1%的TFA)等梯度洗脱5min,10%至80%的乙腈—H2O(含1%的TFA)梯度洗脱35min,流速50ml/min,采用梯度系统洗脱,循环进样纯化,收集主峰并用分析液相检测纯度,纯化主峰纯度应大于98%。制备洗脱液在30℃~35℃水浴条件下减压浓缩,得到一次纯化物料浓缩液。
将一次纯化收集到的物料浓缩液进行二次除盐纯化,条件为:流动相A相:纯化水;B相:乙腈溶液,检测波长:215nm,流速为30~60ml·min-1。收集目标馏分,将收集到的馏分于水温低于35℃减压浓缩至馏分不再流出,将剩余馏分冻干,得到精制品,并真空冷冻干燥得序列10多肽精制品3.2g,总收率39%,HPLC纯度99.3%。
参考实施例2.序列11的制备
序列11:分子量3741.2;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Phe-Leu-Val-Lys-Gly-Ala-Val-Val-Lys-Leu-Lys-NH2。
本实施例提供序列11多肽的制备方法。
序列11多肽的制备方法:采用提供Fmoc保护的氨基树脂,脱除氨基树脂上的Fmoc保护基后,合成序列11多肽肽树脂,脱除树脂及侧链保护基获得序列11多肽粗品,序列11多肽粗品经制备纯化得序列11多肽精制品。
(1)序列11多肽肽树脂的制备:
在100ml的固相反应器中加入Rink Amide-MBHA Resin树脂(5.0g,0.42mmol/g,2.1mmol)及40ml CH2Cl2,将树脂溶胀30min,抽除CH2Cl2,用30ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,再次用30ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,采用DMF(6×40ml)洗涤树脂,备用;同时将3.0g Fmoc-Lys(Boc)-OH(6.3mmol)和0.9g HOBt(6.6mmol)置于100ml烧瓶中,加入40ml DMF溶解,冰浴降温至0~5℃,滴加1.0ml DIC(6.6mmol),加完后反应5min,将该反应液转移至上述所得脱除Fmoc的氨基树脂中,N2鼓泡混匀,缩合反应3h后,抽除反应液,用DMF(6×40ml)洗涤树脂。
重复上述脱保护及缩合步骤,采用逐一偶联的方式,继续依次偶联Fmoc-Leu-OH、Fmoc-Lys(Boc)-OH、Fmoc-Val-OH、Fmoc-Val-OH、Fmoc-Ala-OH、Fmoc-Gly-OH、Fmoc-Lys(Boc)-OH、Fmoc-Val-OH、Fmoc-Leu-OH、Fmoc-Phe-OH、Fmoc-Ala-OH、Fmoc-Ile-OH、Fmoc-Phe-OH、Fmoc-Glu(Otbu)-OH、Fmoc-Lys(Boc)-OH、Fmoc-Ala-OH、Fmoc-Ala-OH、Fmoc-Gln(Trt)-OH、Fmoc-Gly-OH、Fmoc-Glu(Otbu)-OH、Fmoc-Leu-OH、Fmoc-Tyr(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Val-OH、Fmoc-Asp(Otbu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Thr(tBu)-OH、Fmoc-Phe-OH、Fmoc-Thr(tBu)-OH、Fmoc-Gly-OH、Fmoc-Glu(Otbu)-OH、、Fmoc-Ala-OH、Fmoc-His(Trt)-OH直至完成氨基树脂负载的序列11多肽肽树脂的合成,其中脱保护与缩合的步骤基本相同。合成完毕,用DMF(6×40ml)洗涤树脂,向固相反应器中加入40ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,再次用40ml20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,采用DMF(4×40ml)洗涤树脂,再用MeOH(2×40ml)洗涤树脂,35℃真空烘干燥肽树脂。
(2)序列11多肽粗品的制备:
将以上制得的氨基树脂负载的序列11多肽肽树脂加入150ml TFA/TIS/H2O(v/v/v=95:2.5:2.5)混合溶液脱除树脂和侧链保护基,2.5h后抽滤,收集滤液,再用TFA/TIS/H2O(体积比为95:2.5:2.5)混合溶液(10ml)洗涤树脂,抽滤,合并滤液,35℃以下,减压浓缩至馏分不再流出,将浓缩液缓慢倒入3L冷乙醚中,搅拌,析出白色沉淀,过滤,滤饼碾碎,再用冷乙醚洗涤3次,35℃真空干燥5小时,得序列11多肽粗品7.1g,收率:90.3%,HPLC纯度:55.1%。
(3)序列11多肽精制品的制备:
将7.1g序列11多肽粗品溶于20ml 10%醋酸水溶液中,0.45μm膜过滤,用制备型HPLC纯化:选用C18柱子上样,每次上样2~2.5g,波长214nm,(10%乙腈—H2O(含1%的TFA)等梯度洗脱5min,10%至80%的乙腈—H2O(含1%的TFA)梯度洗脱35min,洗脱流速50ml/min,采用梯度系统洗脱,循环进样纯化,收集主峰并用分析液相检测纯度,纯化主峰纯度应大于98%。制备洗脱液在30℃~35℃水浴条件下减压浓缩,得到一次纯化物料浓缩液。
将一次纯化收集到的物料浓缩液进行二次除盐纯化,条件为:流动相A相:纯化水;B相:乙腈溶液,检测波长:215nm,流速为30~60ml·min-1。收集目标馏分,将收集到的馏分于水温低于35℃减压浓缩至馏分不再流出,将剩余馏分冻干,得到精制品,并真空冷冻干燥,得序列11多肽精制品3.1g,总收率39.6%,HPLC纯度99.5%。
参考实施例3.序列12的制备
序列12:分子量3968.5;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Phe-Leu-Val-Lys-Gly-Glu-Leu-Lys-Leu-Leu-Leu-Arg-NH2。
本实施例提供序列12多肽的制备方法。
序列12多肽的制备方法:采用提供Fmoc保护的氨基树脂,脱除氨基树脂上的Fmoc保护基后,合成序列12多肽肽树脂,脱除树脂及侧链保护基获得序列12多肽粗品,序列12多肽粗品经制备纯化得序列12多肽精制品。
(1)序列12多肽肽树脂的制备:
在100ml的固相反应器中加入Rink Amide-MBHA Resin树脂(5.0g,0.42mmol/g,2.1mmol)及40ml CH2Cl2,将树脂溶胀30min,抽除CH2Cl2,用30ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,再次用30ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,采用DMF(6×40ml)洗涤树脂,备用;同时将4.1g Fmoc-Arg(pbf)-OH(6.3mmol)和0.9g HOBt(6.6mmol)置于100ml烧瓶中,加入40ml DMF溶解,冰浴降温至0~5℃,滴加1.0ml DIC(6.6mmol),加完后反应5min,将该反应液转移至上述所得脱除Fmoc的氨基树脂中,N2鼓泡混匀,缩合反应3h后,抽除反应液,用DMF(6×40ml)洗涤树脂。
重复上述脱保护及缩合步骤,采用逐一偶联的方式,继续依次偶联Fmoc-Leu-OH、Fmoc-Leu-OH、Fmoc-Leu-OH、Fmoc-Lys(Boc)-OH、Fmoc-Leu-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Gly-OH、Fmoc-Lys(Boc)-OH、Fmoc-Val-OH、Fmoc-Leu-OH、Fmoc-Phe-OH、Fmoc-Ala-OH、Fmoc-Ile-OH、Fmoc-Phe-OH、Fmoc-Glu(Otbu)-OH、Fmoc-Lys(Boc)-OH、Fmoc-Ala-OH、Fmoc-Ala-OH、Fmoc-Gln(Trt)-OH、Fmoc-Gly-OH、Fmoc-Glu(Otbu)-OH、Fmoc-Leu-OH、Fmoc-Tyr(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Val-OH、Fmoc-Asp(Otbu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Thr(tBu)-OH、Fmoc-Phe-OH、Fmoc-Thr(tBu)-OH、Fmoc-Gly-OH、Fmoc-Glu(Otbu)-OH、、Fmoc-Ala-OH、Fmoc-His(Trt)-OH直至完成氨基树脂负载的序列12多肽肽树脂的合成,其中脱保护与缩合的步骤基本相同。合成完毕,用DMF(6×40ml)洗涤树脂,向固相反应器中加入40ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,再次用40ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,采用DMF(4×40ml)洗涤树脂,再用MeOH(2×40ml)洗涤树脂,35℃真空烘干燥肽树脂。
(2)序列12多肽粗品的制备:
将以上制得的氨基树脂负载的序列12多肽肽树脂加入150ml TFA/TIS/H2O(v/v/v=95:2.5:2.5)混合溶液脱除树脂和侧链保护基,2.5h后抽滤,收集滤液,再用TFA/TIS/H2O(体积比为95:2.5:2.5)混合溶液(10ml)洗涤树脂,抽滤,合并滤液,35℃以下,减压浓缩至馏分不再流出,将浓缩液缓慢倒入3L冷乙醚中,搅拌,析出白色沉淀,过滤,滤饼碾碎,再用冷乙醚洗涤3次,35℃真空干燥5小时,得序列12多肽粗品7.2g,收率:86.5%,HPLC纯度:52.0%。
(3)序列12多肽精制品的制备:
将7.2g序列12多肽粗品溶于20ml 10%醋酸水溶液中,0.45μm膜过滤,用制备型HPLC纯化:选用C18柱子上样,每次上样1.8~2.2g,波长214nm,(10%乙腈—H2O(含1%的TFA)等梯度洗脱5min,10%至80%的乙腈—H2O(含1%的TFA)梯度洗脱35min,流速50ml/min,采用梯度系统洗脱,循环进样纯化,收集主峰并用分析液相检测纯度,纯化主峰纯度应大于98%。制备洗脱液在30℃~35℃水浴条件下减压浓缩,得到一次纯化物料浓缩液。
将一次纯化收集到的物料浓缩液进行二次除盐纯化,条件为:流动相A相:纯化水;B相:乙腈溶液,检测波长:215nm,流速为30~60ml·min-1。收集目标馏分,将收集到的馏分于水温低于35℃减压浓缩至馏分不再流出,将剩余馏分冻干,得到精制品,并真空冷冻干燥得序列12多肽精制品3.2g,总收率38.1%,HPLC纯度98.7%。
参考实施例4.序列13的制备
序列13:分子量3938.5;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Phe-Leu-Val-Lys-Gly-Val-Leu-Lys-Leu-Leu-Leu-Arg-NH2。
本实施例提供序列13多肽的制备方法。
序列13多肽的制备方法:采用提供Fmoc保护的氨基树脂,脱除氨基树脂上的Fmoc保护基后,合成序列13多肽肽树脂,脱除树脂及侧链保护基获得序列13多肽粗品,序列13多肽粗品经制备纯化得序列13多肽精制品。
(1)序列13多肽肽树脂的制备:
在100ml的固相反应器中加入Rink Amide-MBHA Resin树脂(5.0g,0.42mmol/g,2.1mmol)及40ml CH2Cl2,将树脂溶胀30min,抽除CH2Cl2,用30ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,再次用30ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,采用DMF(6×40ml)洗涤树脂,备用;同时将4.1g Fmoc-Arg(pbf)-OH(6.3mmol)和0.9g HOBt(6.6mmol)置于100ml烧瓶中,加入40ml DMF溶解,冰浴降温至0~5℃,滴加1.0ml DIC(6.6mmol),加完后反应5min,将该反应液转移至上述所得脱除Fmoc的氨基树脂中,N2鼓泡混匀,缩合反应3h后,抽除反应液,用DMF(6×40ml)洗涤树脂。
重复上述脱保护及缩合步骤,采用逐一偶联的方式,继续依次偶联Fmoc-Leu-OH、Fmoc-Leu-OH、Fmoc-Leu-OH、Fmoc-Lys(Boc)-OH、Fmoc-Leu-OH、Fmoc-Val-OH、Fmoc-Gly-OH、Fmoc-Lys(Boc)-OH、Fmoc-Val-OH、Fmoc-Leu-OH、Fmoc-Phe-OH、Fmoc-Ala-OH、Fmoc-Ile-OH、Fmoc-Phe-OH、Fmoc-Glu(Otbu)-OH、Fmoc-Lys(Boc)-OH、Fmoc-Ala-OH、Fmoc-Ala-OH、Fmoc-Gln(Trt)-OH、Fmoc-Gly-OH、Fmoc-Glu(Otbu)-OH、Fmoc-Leu-OH、Fmoc-Tyr(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Val-OH、Fmoc-Asp(Otbu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Thr(tBu)-OH、Fmoc-Phe-OH、Fmoc-Thr(tBu)-OH、Fmoc-Gly-OH、Fmoc-Glu(Otbu)-OH、、Fmoc-Ala-OH、Fmoc-His(Trt)-OH直至完成氨基树脂负载的序列13多肽肽树脂的合成,其中脱保护与缩合的步骤基本相同。合成完毕,用DMF(6×40ml)洗涤树脂,向固相反应器中加入40ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,再次用40ml20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,采用DMF(4×40ml)洗涤树脂,再用MeOH(2×40ml)洗涤树脂,35℃真空烘干燥肽树脂。
(2)序列13多肽粗品的制备:
将以上制得的氨基树脂负载的序列13多肽肽树脂加入150ml TFA/TIS/H2O(v/v/v=95:2.5:2.5)混合溶液脱除树脂和侧链保护基,2.5h后抽滤,收集滤液,再用TFA/TIS/H2O(体积比为95:2.5:2.5)混合溶液(10ml)洗涤树脂,抽滤,合并滤液,35℃以下,减压浓缩至馏分不再流出,将浓缩液缓慢倒入3L冷乙醚中,搅拌,析出白色沉淀,过滤,滤饼碾碎,再用冷乙醚洗涤3次,35℃真空干燥5小时,得序列13多肽粗品7.1g,收率:85.7%,HPLC纯度:56.9%。
(3)序列13多肽精制品的制备:
将7.1g序列13多肽粗品溶于20ml 10%醋酸水溶液中,0.45μm膜过滤,用制备型HPLC纯化:选用C18柱子上样,每次上样1.8~2.2g,波长214nm,(10%乙腈—H2O(含1%的TFA)等梯度洗脱5min,10%至80%的乙腈—H2O(含1%的TFA)梯度洗脱35min,流速50ml/min,采用梯度系统洗脱,循环进样纯化,收集主峰并用分析液相检测纯度,纯化主峰纯度应大于98%。制备洗脱液在30℃~35℃水浴条件下减压浓缩,得到一次纯化物料浓缩液。
将一次纯化收集到的物料浓缩液进行二次除盐纯化,条件为:流动相A相:纯化水;B相:乙腈溶液,检测波长:215nm,流速为30~60ml·min-1。收集目标馏分,将收集到的馏分于水温低于35℃减压浓缩至馏分不再流出,将剩余馏分冻干,得到精制品,并真空冷冻干燥得序列13多肽精制品3.2g,总收率38.6%,HPLC纯度99.1%。
参考实施例5.序列14的制备
序列14:分子量3797.3;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Phe-Leu-Val-Lys-Gly-Val-Leu-Leu-Leu-Lys-Lys-NH2。
本实施例提供序列14多肽的制备方法。
序列14多肽的制备方法:采用提供Fmoc保护的氨基树脂,脱除氨基树脂上的Fmoc保护基后,合成序列14多肽肽树脂,脱除树脂及侧链保护基获得序列14多肽粗品,序列14多肽粗品经制备纯化得序列14多肽精制品。
(1)序列14多肽肽树脂的制备:
在100ml的固相反应器中加入Rink Amide-MBHA Resin树脂(5.0g,0.42mmol/g,2.1mmol)及40ml CH2Cl2,将树脂溶胀30min,抽除CH2Cl2,用30ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,再次用30ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,采用DMF(6×40ml)洗涤树脂,备用;同时将3.0g Fmoc-Lys(Boc)-OH(6.3mmol)和0.9g HOBt(6.6mmol)置于100ml烧瓶中,加入40ml DMF溶解,冰浴降温至0~5℃,滴加1.0ml DIC(6.6mmol),加完后反应5min,将该反应液转移至上述所得脱除Fmoc的氨基树脂中,N2鼓泡混匀,缩合反应3h后,抽除反应液,用DMF(6×40ml)洗涤树脂。
重复上述脱保护及缩合步骤,采用逐一偶联的方式,继续依次偶联Fmoc-Lys(Boc)-OH、Fmoc-Leu-OH、Fmoc-Leu-OH、Fmoc-Leu-OH、Fmoc-Val-OH、Fmoc-Gly-OH、Fmoc-Lys(Boc)-OH、Fmoc-Val-OH、Fmoc-Leu-OH、Fmoc-Phe-OH、Fmoc-Ala-OH、Fmoc-Ile-OH、Fmoc-Phe-OH、Fmoc-Glu(Otbu)-OH、Fmoc-Lys(Boc)-OH、Fmoc-Ala-OH、Fmoc-Ala-OH、Fmoc-Gln(Trt)-OH、Fmoc-Gly-OH、Fmoc-Glu(Otbu)-OH、Fmoc-Leu-OH、Fmoc-Tyr(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Val-OH、Fmoc-Asp(Otbu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Thr(tBu)-OH、Fmoc-Phe-OH、Fmoc-Thr(tBu)-OH、Fmoc-Gly-OH、Fmoc-Glu(Otbu)-OH、、Fmoc-Ala-OH、Fmoc-His(Trt)-OH直至完成氨基树脂负载的序列14多肽肽树脂的合成,其中脱保护与缩合的步骤基本相同。合成完毕,用DMF(6×40ml)洗涤树脂,向固相反应器中加入40ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,再次用40ml20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,采用DMF(4×40ml)洗涤树脂,再用MeOH(2×40ml)洗涤树脂,35℃真空烘干燥肽树脂。
(2)序列14多肽粗品的制备:
将以上制得的氨基树脂负载的序列14多肽肽树脂加入150ml TFA/TIS/H2O(v/v/v=95:2.5:2.5)混合溶液脱除树脂和侧链保护基,2.5h后抽滤,收集滤液,再用TFA/TIS/H2O(体积比为95:2.5:2.5)混合溶液(10ml)洗涤树脂,抽滤,合并滤液,35℃以下,减压浓缩至馏分不再流出,将浓缩液缓慢倒入3L冷乙醚中,搅拌,析出白色沉淀,过滤,滤饼碾碎,再用冷乙醚洗涤3次,35℃真空干燥5小时,得序列14多肽粗品6.4g,收率:84.1%,HPLC纯度:50.3%。
(3)序列14多肽精制品的制备:
将6.4g序列14多肽粗品溶于20ml 10%醋酸水溶液中,0.45μm膜过滤,用制备型HPLC纯化:选用C18柱子上样,每次上样1.8~2.2g,波长214nm,(10%乙腈—H2O(含1%的TFA)等梯度洗脱5min,10%至80%的乙腈—H2O(含1%的TFA)梯度洗脱35min,洗脱流速50ml/min,采用梯度系统洗脱,循环进样纯化,收集主峰并用分析液相检测纯度,纯化主峰纯度应大于98%。制备洗脱液在30℃~35℃水浴条件下减压浓缩,得到一次纯化物料浓缩液。
将一次纯化收集到的物料浓缩液进行二次除盐纯化,条件为:流动相A相:纯化水;B相:乙腈溶液,检测波长:215nm,流速为30~60ml·min-1。收集目标馏分,将收集到的馏分于水温低于35℃减压浓缩至馏分不再流出,将剩余馏分冻干,得到精制品,并真空冷冻干燥,得序列14多肽精制品2.8g,总收率36.6%,HPLC纯度98.5%。
参考实施例6.序列15的制备
序列15:分子量3900.4;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-His-Leu-Val-Lys-Gly-Ala-Leu-Lys-Leu-Leu-Leu-Arg-NH2。
本实施例提供序列15多肽的制备方法。
序列15多肽的制备方法:采用提供Fmoc保护的氨基树脂,脱除氨基树脂上的Fmoc保护基后,合成序列15多肽肽树脂,脱除树脂及侧链保护基获得序列15多肽粗品,序列15多肽粗品经制备纯化得序列15多肽精制品。
(1)序列15多肽肽树脂的制备:
在100ml的固相反应器中加入Rink Amide-MBHA Resin树脂(5.0g,0.42mmol/g,2.1mmol)及40ml CH2Cl2,将树脂溶胀30min,抽除CH2Cl2,用30ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,再次用30ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,采用DMF(6×40ml)洗涤树脂,备用;同时将4.1g Fmoc-Arg(pbf)-OH(6.3mmol)和0.9g HOBt(6.6mmol)置于100ml烧瓶中,加入40ml DMF溶解,冰浴降温至0~5℃,滴加1.0ml DIC(6.6mmol),加完后反应5min,将该反应液转移至上述所得脱除Fmoc的氨基树脂中,N2鼓泡混匀,缩合反应3h后,抽除反应液,用DMF(6×40ml)洗涤树脂。
重复上述脱保护及缩合步骤,采用逐一偶联的方式,继续依次偶联Fmoc-Leu-OH、Fmoc-Leu-OH、Fmoc-Leu-OH、Fmoc-Lys(Boc)-OH、Fmoc-Leu-OH、Fmoc-Ala-OH、Fmoc-Gly-OH、Fmoc-Lys(Boc)-OH、Fmoc-Val-OH、Fmoc-Leu-OH、Fmoc-His(Trt)-OH、Fmoc-Ala-OH、Fmoc-Ile-OH、Fmoc-Phe-OH、Fmoc-Glu(Otbu)-OH、Fmoc-Lys(Boc)-OH、Fmoc-Ala-OH、Fmoc-Ala-OH、Fmoc-Gln(Trt)-OH、Fmoc-Gly-OH、Fmoc-Glu(Otbu)-OH、Fmoc-Leu-OH、Fmoc-Tyr(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Val-OH、Fmoc-Asp(Otbu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Thr(tBu)-OH、Fmoc-Phe-OH、Fmoc-Thr(tBu)-OH、Fmoc-Gly-OH、Fmoc-Glu(Otbu)-OH、、Fmoc-Ala-OH、Fmoc-His(Trt)-OH直至完成氨基树脂负载的序列15多肽肽树脂的合成,其中脱保护与缩合的步骤基本相同。合成完毕,用DMF(6×40ml)洗涤树脂,向固相反应器中加入40ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,再次用40ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,采用DMF(4×40ml)洗涤树脂,再用MeOH(2×40ml)洗涤树脂,35℃真空烘干燥肽树脂。
(2)序列15多肽粗品的制备:
将以上制得的氨基树脂负载的序列15多肽肽树脂加入150ml TFA/TIS/H2O(v/v/v=95:2.5:2.5)混合溶液脱除树脂和侧链保护基,2.5h后抽滤,收集滤液,再用TFA/TIS/H2O(体积比为95:2.5:2.5)混合溶液(10ml)洗涤树脂,抽滤,合并滤液,35℃以下,减压浓缩至馏分不再流出,将浓缩液缓慢倒入3L冷乙醚中,搅拌,析出白色沉淀,过滤,滤饼碾碎,再用冷乙醚洗涤3次,35℃真空干燥5小时,得序列15多肽粗品7.0g,收率:85.8%,HPLC纯度:53.7%。
(3)序列15多肽精制品的制备:
将7.0g序列15多肽粗品溶于20ml 10%醋酸水溶液中,0.45μm膜过滤,用制备型HPLC纯化:选用C18柱子上样,每次上样1.8~2.2g,波长214nm,(10%乙腈—H2O(含1%的TFA)等梯度洗脱5min,10%至80%的乙腈—H2O(含1%的TFA)梯度洗脱35min,流速50ml/min,采用梯度系统洗脱,循环进样纯化,收集主峰并用分析液相检测纯度,纯化主峰纯度应大于98%。制备洗脱液在30℃~35℃水浴条件下减压浓缩,得到一次纯化物料浓缩液。
将一次纯化收集到的物料浓缩液进行二次除盐纯化,条件为:流动相A相:纯化水;B相:乙腈溶液,检测波长:215nm,流速为30~60ml·min-1。收集目标馏分,将收集到的馏分于水温低于35℃减压浓缩至馏分不再流出,将剩余馏分冻干,得到精制品,并真空冷冻干燥得序列15多肽精制品3.1g,总收率37.6%,HPLC纯度98.9%。
参考实施例7.序列16的制备
序列16:分子量3780.3;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Ala-Val-Val-Lys-Leu-Lys-NH2。
本实施例提供序列16多肽的制备方法。
序列16多肽的制备方法:采用提供Fmoc保护的氨基树脂,脱除氨基树脂上的Fmoc保护基后,合成序列16多肽肽树脂,脱除树脂及侧链保护基获得序列16多肽粗品,序列16多肽粗品经制备纯化得序列16多肽精制品。
(1)序列16多肽肽树脂的制备:
在100ml的固相反应器中加入Rink Amide-MBHA Resin树脂(5.0g,0.42mmol/g,2.1mmol)及40ml CH2Cl2,将树脂溶胀30min,抽除CH2Cl2,用30ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,再次用30ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,采用DMF(6×40ml)洗涤树脂,备用;同时将3.0g Fmoc-Lys(Boc)-OH(6.3mmol)和0.9g HOBt(6.6mmol)置于100ml烧瓶中,加入40ml DMF溶解,冰浴降温至0~5℃,滴加1.0ml DIC(6.6mmol),加完后反应5min,将该反应液转移至上述所得脱除Fmoc的氨基树脂中,N2鼓泡混匀,缩合反应3h后,抽除反应液,用DMF(6×40ml)洗涤树脂。
重复上述脱保护及缩合步骤,采用逐一偶联的方式,继续依次偶联Fmoc-Leu-OH、Fmoc-Lys(Boc)-OH、Fmoc-Val-OH、Fmoc-Val-OH、Fmoc-Ala-OH、Fmoc-Gly-OH、Fmoc-Lys(Boc)-OH、Fmoc-Val-OH、Fmoc-Leu-OH、Fmoc-Trp(Boc)-OH、Fmoc-Ala-OH、Fmoc-Ile-OH、Fmoc-Phe-OH、Fmoc-Glu(Otbu)-OH、Fmoc-Lys(Boc)-OH、Fmoc-Ala-OH、Fmoc-Ala-OH、Fmoc-Gln(Trt)-OH、Fmoc-Gly-OH、Fmoc-Glu(Otbu)-OH、Fmoc-Leu-OH、Fmoc-Tyr(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Val-OH、Fmoc-Asp(Otbu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Thr(tBu)-OH、Fmoc-Phe-OH、Fmoc-Thr(tBu)-OH、Fmoc-Gly-OH、Fmoc-Glu(Otbu)-OH、、Fmoc-Ala-OH、Fmoc-His(Trt)-OH直至完成氨基树脂负载的序列16多肽肽树脂的合成,其中脱保护与缩合的步骤基本相同。合成完毕,用DMF(6×40ml)洗涤树脂,向固相反应器中加入40ml 20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,再次用40ml20%哌啶/DMF溶液脱除树脂上的Fmoc保护基,10min后,抽除反应液,采用DMF(4×40ml)洗涤树脂,再用MeOH(2×40ml)洗涤树脂,35℃真空烘干燥肽树脂。
(2)序列16多肽粗品的制备:
将以上制得的氨基树脂负载的序列16多肽肽树脂加入150ml TFA/TIS/H2O(v/v/v=95:2.5:2.5)混合溶液脱除树脂和侧链保护基,2.5h后抽滤,收集滤液,再用TFA/TIS/H2O(体积比为95:2.5:2.5)混合溶液(10ml)洗涤树脂,抽滤,合并滤液,35℃以下,减压浓缩至馏分不再流出,将浓缩液缓慢倒入3L冷乙醚中,搅拌,析出白色沉淀,过滤,滤饼碾碎,再用冷乙醚洗涤3次,35℃真空干燥5小时,得序列16多肽粗品7.1g,收率:89.7%,HPLC纯度:56.8%。
(3)序列16多肽精制品的制备:
将7.1g序列16多肽粗品溶于20ml 10%醋酸水溶液中,0.45μm膜过滤,用制备型HPLC纯化:选用C18柱子上样,每次上样2~2.5g,波长214nm,(10%乙腈—H2O(含1%的TFA)等梯度洗脱5min,10%至80%的乙腈—H2O(含1%的TFA)梯度洗脱35min,洗脱流速50ml/min,采用梯度系统洗脱,循环进样纯化,收集主峰并用分析液相检测纯度,纯化主峰纯度应大于98%。制备洗脱液在30℃~35℃水浴条件下减压浓缩,得到一次纯化物料浓缩液。
将一次纯化收集到的物料浓缩液进行二次除盐纯化,条件为:流动相A相:纯化水;B相:乙腈溶液,检测波长:215nm,流速为30~60ml·min-1。收集目标馏分,将收集到的馏分于水温低于35℃减压浓缩至馏分不再流出,将剩余馏分冻干,得到精制品,并真空冷冻干燥,得序列16多肽精制品3.1g,总收率39.4%,HPLC纯度99.6%。
验证实施例1.测定本发明GLP-1化合物融合蛋白的体外活性
如下所述测定GLP-1的类似物的效价,即在含有表达人GLP-1受体的膜的培养基中刺激环AMP(cAMP)的形成。
用目的GLP-1类似物或衍生物刺激表达人GLP-1受体的来自稳定转染的细胞系BHK467-12A(tk-ts13)的纯化的质膜,用来自PerkinElmer Life Sciences的AlphaScreenTM cAMP测定试剂盒测量产生cAMP的效价。AlphaScreen测定的基本原理是内源cAMP和外源加入的生物素-cAMP之间的竞争。通过用与受体珠缀合的特异性抗体实现cAMP捕获。
细胞培养和膜的制备:选择稳定转染的细胞系和高表达克隆用于筛选。让细胞在DMEM、5%FCS、1%Pen/Strep(青霉素/链霉素)和0.5mg/ml的选择标记G418中于5%CO2生长。
用PBS洗涤2X大约80%汇合的细胞,用Versene(乙二胺四乙酸四钠盐的水溶液)收获,以1000rpm离心5分钟,去掉上清液。另外的步骤都在冰上进行。通过Ultrathurax让细胞沉淀在10ml缓冲液1(20mM Na-HEPES、10mM EDTA、pH=7.4)中均质化20-30秒,以20,000rpm离心15分钟,将沉淀重悬于10ml缓冲液2(20mMNa-HEPES、0.1mM EDTA、pH=7.4)中。让悬浮液均质化20-30秒,以20,000rpm离心15分钟。让缓冲液2中的悬浮液再次重复均质化和离心,将膜重悬于缓冲液2中。测定蛋白质浓度,将膜储存在-80℃直到使用。
在平底的1/2-面积的96-孔板中实施测定。最终体积为每孔50μl。
溶液和反应试剂如下:
来自Perkin Elmer Life Sciences的AlphaScreen cAMP测定试剂盒;含有抗-cAMP受体珠(10U/μl)、链霉抗生物素供体珠(10U/μl)和生物素化的-cAMP(133U/μl)。
AlphaScreen缓冲液,pH=7.4:50mM TRIS-HCl;5mM HEPES;10mM MgCl2,6H2O;150mM NaCl;0.01%吐温。使用前将以下加入到AlphaScreen缓冲液中(指最终浓度):BSA:0.1%;IBMX:0.5mM;ATP:1mM;GTP:1uM。
cAMP标准(测定中稀释系数=5):cAMP溶液:5μL的5mMcAMP-储液+495μLAlphaScreen缓冲液。
在AlphaScreen缓冲液中制备cAMP标准以及待测GLP-1类似物或衍生物的合适的稀释系列,例如以下8种浓度的GLP-1化合物:10-7、10-8、10-9、10-10、10-11、10-12、10-13和10-14M和例如cAMP的系列10-6至3×10-11。
膜/受体珠:使用hGLP-1/BHK 467-12A膜;6μg/孔对应于0.6mg/ml(每孔所用膜量可变化)。
“无膜”:AlphaScreen缓冲液中的受体珠(最终15μg/ml)
“6μg/孔膜”:AlphaScreen缓冲液中的膜+受体珠(最终15μg/ml)。
加10μl“无膜”到cAMP标准(每孔一式二份)、阳性和阴性对照中。
加10μl“6μg/孔膜”到GLP-1和类似物(每孔一式二份/一式三份)
阳性对照:10μl“无膜”+10μl AlphaScreen缓冲液
阴性对照:10μl“无膜”+10μl cAMP储液(50μM)
因为珠对直接光照敏感,所以任何处理都在黑暗(尽可能黑)或在绿光中。在冰上进行所有稀释。
操作方法:
制备AlphaScreen缓冲液;
在AlphaScreen缓冲液中溶解并稀释GLP-1/类似物/cAMP标准;
制备供体珠溶液并在R.T孵育30分钟;
将cAMP/GLP-1/类似物加到板中:每孔10μl;
制备膜/受体珠溶液,并将其加到板中:每孔10μl;
加入供体珠:每孔30μl;
用铝箔包裹板,于RT在振荡器中孵育3小时(极为缓慢);
在AlphaScreen上计数-在AlphaScreen中计数前让每一板预孵育3分钟;
用Graph-Pad Prism软件(版本5)计算EC50[pM]值,结果见表1。
杜拉糖肽EC50值为13.712nM,HIP925-1的EC50值为0.124nM。HIP925-1~12效果接近。
表1.各融合蛋白的体外活性EC50值比较
融合蛋白 | EC50(nM) |
HIP925-1 | 0.124 |
HIP925-2 | 0.266 |
HIP925-3 | 0.422 |
HIP925-4 | 1.425 |
HIP925-5 | 1.057 |
HIP925-6 | 2.589 |
HIP925-7 | 2.874 |
HIP925-8 | 2.771 |
HIP925-9 | 1.732 |
HIP925-10 | 2.225 |
HIP925-11 | 2.527 |
HIP925-12 | 2.449 |
杜拉鲁肽 | 15.712 |
验证实施例2.接头对融合的GLP-1类似物肽的活性的影响
比较肽接头SEQ ID NO:4-8对活性的影响。按照上述实施例中所述的cAMP测定方法测试不同接头的融合肽对人GLP-1受体的活性。所测试的融合分子能够在cAMP细胞基测定中活化人GLP-1受体。在该测定中,接头序列4、6和7稍优于5和8。
验证实施例3.db/db糖尿病小鼠单次注射的血糖变化情况
雄性糖尿病db/db小鼠,8周龄,体重42±2g,按体重随机分为5组,每组6只。受试药组按1.5mg/kg剂量皮下注射HIP925-1~12,阳性组注射1.5mg/kg的杜拉鲁肽,模型组注射等体积剂量(10mL/kg)的PBS缓冲液。各组动物分别于给药前(0h)、给药后1h、2h、4h、6h、24h、48h、72h、96h、120h、144h、168h、180h、192h、204h、216h、228h、240h和252h,再分别腹腔注射40%的葡萄糖溶液200μl,给予葡萄糖后30、60分钟尾静脉取血测定血糖值RBG(血糖仪测定)。血糖数据以均数±标准差(means±SD)形式表示,采用SPSS18.0统计软件分析数据。正态分布,多组间均数差异采用单因素方差分析,方差齐性采用LSD检验,方差不齐采用Dunnett-T3检验;非正态性分布采用非参数检验,P<0.05表示具有显著性统计学差异。
在相同剂量下,实验组和阳性对照药杜拉鲁肽均有降血糖作用。经t-test检验,在0h~6h,HIP925-1~12组与杜拉鲁肽组动物的随机血糖值相对模型组均出现显著性降低,P<0.01,说明二者在体内的起效时间相近,短期内降糖效果相似;另外从给药后9天内小鼠RBG值变化中得知,杜拉鲁肽降血糖作用能维持至第3.5天,在给药后第100小时,其血糖值与模型组相比已不具有统计学差异,而HIP925-1~12组能维持至给药后228-252小时,即第10.5天小鼠的血糖水平与模型组相比,仍具有统计学差异(P<0.05),其中HIP925-1组能维持至给药后252h,HIP925-9组能维持至给药后228h。本发明其他融合蛋白稳定性也高于杜拉糖肽。因此,本发明所述融合蛋白稳定性高,有望开发成每周或更长周期给药一次的长效GLP-1受体激动剂。
表2.各融合蛋白维持降糖效果的持续时间比较
融合蛋白 | 维持降糖效果的持续时间(h) |
HIP925-1 | 252 |
HIP925-2 | 248 |
HIP925-3 | 246 |
HIP925-4 | 248 |
HIP925-5 | 243 |
HIP925-6 | 242 |
HIP925-7 | 242 |
HIP925-8 | 238 |
HIP925-9 | 228 |
HIP925-10 | 232 |
HIP925-11 | 235 |
HIP925-12 | 229 |
杜拉鲁肽 | 100 |
验证实施例4.db/db糖尿病小鼠连续10周给予HIP925-1~12的随机血糖及HbA1c含量变化
SPF级雄性db/db小鼠(购自上海斯莱克实验动物有限公司),8周龄,适应性饲养1周后,将30只db/db小鼠按随机血糖值(random blood glucose,RBG)随机分为5组(n=6):模型组、杜拉鲁肽组、HIP925-1~12按低(0.75mg/kg)、中(1.5mg/kg)、高(3mg/kg)剂量给药。各给药组皮下注射给予相应剂量的药物溶液,模型组皮下注射PBS缓冲液,给药体积均为10ml/kg。各组动物每周给药一次,连续给药10周,分别用血糖仪(安准血糖仪,长沙三诺生物传感股份有限公司产品)检测给药后不同采血时间点各组小鼠RBG值,并记录数据。采血时间点设定:第一次给药前(0d)、给药后第7d、14d、21d、28d、35d、42d、49d、56d、63d和70d。第70d,各组小鼠禁食14h后眼眶取血,然后立即用糖化血红蛋白测定试剂盒(免疫比浊法)及其配套仪器H700特定蛋白分析仪检测全血中糖化血红蛋白(HbA1c)含量,结果以HbA1c占总血红蛋白的百分比(%)表示。
数据以均数±标准差(means±SD)形式表示,采用SPSS18.0统计软件分析数据。正态分布,多组间均数差异采用单因素方差分析,方差齐性采用Dunnett-t检验,方差不齐采用Dunnett-t3检验;非正态性分布采用非参数检验,P<0.05表示具有显著性统计学差异。
对各组小鼠连续给药10周随机血糖值的变化趋势研究发现,HIP925-1~12高、中、低剂量组的小鼠血糖值相对模型组都有一定程度的降低,并且其降血糖活性呈现剂量依赖性。提示HIP925-1~12能有效、持续地控制db/db糖尿病小鼠的血糖水平。而且,首次给药和末次给药HIP925-1~12的降糖效果相似,说明未出现HIP925-1~12长期给药导致的受体敏感性降低的作用。
糖化血红蛋白(HbA1c)是血中葡萄糖与红细胞的血红蛋白相结合的产物,它与血中的葡萄糖水平呈正比的关系。由于红细胞在血循环中的寿命约为120天,因此糖化血红蛋白可反映取血前4-12周血糖的总水平,弥补了空腹血糖只反映瞬时血糖的不足。因而,HbA1c是长期控制血糖最重要的评估指标,也是临床决定是否要更换治疗方案的重要依据。本实施例中HbA1c检查结果可以稳定、可靠的反映出取血前2~3个月小鼠的血糖控制情况。连续给药10周后各组小鼠HbA1c含量测定结果见下表3。
表3.HIP925-1对db/db小鼠随机血糖的影响(means±SD,n=6)
注:各剂量组与模型组相比*P<0.05;**P<0.01。单位mmol/L。
而且,HIP925-1每周一次0.75mg治疗组受试者HbAlc降至正常水平(HbAlc<7%)的比例较每周一次0.75mg杜拉糖肽高12%。HIP925-1~12效果接近。
SEQUENCE LISTING
<110>鲁南制药集团股份有限公司3
<120> 一种GLP-1类似物融合蛋白质 GLP-1
<160> 31
<170> PatentIn version 3.5
<210> 1
<211> 229
<212> PRT
<213> synthetic construct
<220>
<221> UNSURE
<222> (11)..(11)
<223> Xaa at position 11 is Pro
<220>
<221> UNSURE
<222> (85)..(85)
<223> Xaa at position 85 is Ala or Phe
<220>
<221> UNSURE
<222> (86)..(86)
<223> Xaa at position 86 is Phe or Glu
<220>
<221> UNSURE
<222> (87)..(87)
<223> Xaa at position 87 is Glu, Phe or Leu
<220>
<221> UNSURE
<222> (91)..(91)
<223> Xaa at position 91 is Gly
<400> 1
Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Xaa Cys Pro Ala Pro Glu
1 5 10 15
Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
20 25 30
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
35 40 45
Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
50 55 60
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
65 70 75 80
Ser Thr Tyr Arg Xaa Xaa Xaa Val Leu Thr Xaa Leu His Gln Asp Trp
85 90 95
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
100 105 110
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
115 120 125
Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
130 135 140
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
145 150 155 160
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
165 170 175
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg
180 185 190
Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys
195 200 205
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
210 215 220
Ser Leu Ser Leu Gly
225
<210> 2
<211> 229
<212> PRT
<213> synthetic construct
<400> 2
Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu
1 5 10 15
Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
20 25 30
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
35 40 45
Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
50 55 60
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
65 70 75 80
Ser Thr Tyr Arg Ala Phe Glu Val Leu Thr Gly Leu His Gln Asp Trp
85 90 95
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
100 105 110
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
115 120 125
Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
130 135 140
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
145 150 155 160
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
165 170 175
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg
180 185 190
Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys
195 200 205
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
210 215 220
Ser Leu Ser Leu Gly
225
<210> 3
<211> 229
<212> PRT
<213> synthetic construct
<400> 3
Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu
1 5 10 15
Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
20 25 30
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
35 40 45
Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
50 55 60
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
65 70 75 80
Ser Thr Tyr Arg Phe Glu Phe Val Leu Thr Gly Leu His Gln Asp Trp
85 90 95
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
100 105 110
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
115 120 125
Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
130 135 140
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
145 150 155 160
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
165 170 175
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg
180 185 190
Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys
195 200 205
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
210 215 220
Ser Leu Ser Leu Gly
225
<210> 4
<211> 12
<212> PRT
<213> synthetic construct
<400> 4
Gly Ala Ala Ala Ala Leu Ser Ala Ala Ala Ala Ser
1 5 10
<210> 5
<211> 15
<212> PRT
<213> synthetic construct
<400> 5
Gly Gly Gly Gly Ser Lys Lys Lys Lys Ser Gly Gly Gly Gly Ser
1 5 10 15
<210> 6
<211> 22
<212> PRT
<213> synthetic construct
<400> 6
Gly Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
1 5 10 15
Ser Gly Gly Gly Gly Ser
20
<210> 7
<211> 25
<212> PRT
<213> synthetic construct
<400> 7
Gly Gly Gly Gly Ser Lys Lys Lys Lys Ser Gly Gly Gly Gly Ser Lys
1 5 10 15
Lys Lys Lys Ser Gly Gly Gly Gly Ser
20 25
<210> 8
<211> 15
<212> PRT
<213> synthetic construct
<400> 8
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15
<210> 9
<211> 31
<212> PRT
<213> synthetic construct
<220>
<221> UNSURE
<222> (25)..(25)
<223> Xaa at position 25 is Trp, Phe or His
<220>
<221> UNSURE
<222> (30)..(30)
<223> Xaa at position 30 is Val, Glu or Ala
<220>
<221> UNSURE
<222> (31)..(31)
<223> Xaa at position 31 is Val-Val-Lys-Leu-Lys-NH2,
Ala-Ala-Lys-Gly-Gly-Lys-NH2, Leu-Leu-Leu-Lys-Lys-NH2 or
Leu-Leu-Leu-Trp-Leu-Leu-Leu-Arg-NH2
<400> 9
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Xaa Leu Val Lys Gly Xaa Xaa
20 25 30
<210> 10
<211> 36
<212> PRT
<213> synthetic construct
<400> 10
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Phe Leu Val Lys Gly Ala Leu Lys
20 25 30
Leu Leu Leu Arg
35
<210> 11
<211> 35
<212> PRT
<213> synthetic construct
<400> 11
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Phe Leu Val Lys Gly Ala Val Val
20 25 30
Lys Leu Lys
35
<210> 12
<211> 36
<212> PRT
<213> synthetic construct
<400> 12
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Phe Leu Val Lys Gly Glu Leu Lys
20 25 30
Leu Leu Leu Arg
35
<210> 13
<211> 36
<212> PRT
<213> synthetic construct
<400> 13
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Phe Leu Val Lys Gly Val Leu Lys
20 25 30
Leu Leu Leu Arg
35
<210> 14
<211> 35
<212> PRT
<213> synthetic construct
<400> 14
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Phe Leu Val Lys Gly Val Leu Leu
20 25 30
Leu Lys Lys
35
<210> 15
<211> 36
<212> PRT
<213> synthetic construct
<400> 15
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala His Leu Val Lys Gly Ala Leu Lys
20 25 30
Leu Leu Leu Arg
35
<210> 16
<211> 35
<212> PRT
<213> synthetic construct
<400> 16
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Ala Val Val
20 25 30
Lys Leu Lys
35
<210> 17
<211> 277
<212> PRT
<213> synthetic construct
<400> 17
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Phe Leu Val Lys Gly Ala Leu Lys
20 25 30
Leu Leu Leu Arg Gly Ala Ala Ala Ala Lys Ser Ala Ala Ala Ala Ser
35 40 45
Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu
50 55 60
Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
65 70 75 80
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
85 90 95
Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
100 105 110
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
115 120 125
Ser Thr Tyr Arg Ala Phe Glu Val Leu Thr Gly Leu His Gln Asp Trp
130 135 140
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
145 150 155 160
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
165 170 175
Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
180 185 190
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
195 200 205
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
210 215 220
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg
225 230 235 240
Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys
245 250 255
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
260 265 270
Ser Leu Ser Leu Gly
275
<210> 18
<211> 277
<212> PRT
<213> synthetic construct
<400> 18
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Phe Leu Val Lys Gly Ala Leu Lys
20 25 30
Leu Leu Leu Arg Gly Ala Ala Ala Ala Lys Ser Ala Ala Ala Ala Ser
35 40 45
Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu
50 55 60
Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
65 70 75 80
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
85 90 95
Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
100 105 110
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
115 120 125
Ser Thr Tyr Arg Phe Glu Phe Val Leu Thr Gly Leu His Gln Asp Trp
130 135 140
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
145 150 155 160
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
165 170 175
Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
180 185 190
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
195 200 205
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
210 215 220
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg
225 230 235 240
Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys
245 250 255
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
260 265 270
Ser Leu Ser Leu Gly
275
<210> 19
<211> 276
<212> PRT
<213> synthetic construct
<400> 19
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Phe Leu Val Lys Gly Ala Val Val
20 25 30
Lys Leu Lys Gly Ala Ala Ala Ala Lys Ser Ala Ala Ala Ala Ser Ala
35 40 45
Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe
50 55 60
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
65 70 75 80
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
85 90 95
Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val
100 105 110
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser
115 120 125
Thr Tyr Arg Ala Phe Glu Val Leu Thr Gly Leu His Gln Asp Trp Leu
130 135 140
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser
145 150 155 160
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
165 170 175
Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln
180 185 190
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
195 200 205
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
210 215 220
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu
225 230 235 240
Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser
245 250 255
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
260 265 270
Leu Ser Leu Gly
275
<210> 20
<211> 276
<212> PRT
<213> synthetic construct
<400> 20
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Phe Leu Val Lys Gly Ala Val Val
20 25 30
Lys Leu Lys Gly Ala Ala Ala Ala Lys Ser Ala Ala Ala Ala Ser Ala
35 40 45
Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe
50 55 60
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
65 70 75 80
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
85 90 95
Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val
100 105 110
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser
115 120 125
Thr Tyr Arg Phe Glu Phe Val Leu Thr Gly Leu His Gln Asp Trp Leu
130 135 140
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser
145 150 155 160
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
165 170 175
Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln
180 185 190
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
195 200 205
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
210 215 220
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu
225 230 235 240
Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser
245 250 255
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
260 265 270
Leu Ser Leu Gly
275
<210> 21
<211> 277
<212> PRT
<213> synthetic construct
<400> 21
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Phe Leu Val Lys Gly Glu Leu Lys
20 25 30
Leu Leu Leu Arg Gly Ala Ala Ala Ala Lys Ser Ala Ala Ala Ala Ser
35 40 45
Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu
50 55 60
Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
65 70 75 80
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
85 90 95
Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
100 105 110
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
115 120 125
Ser Thr Tyr Arg Ala Phe Glu Val Leu Thr Gly Leu His Gln Asp Trp
130 135 140
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
145 150 155 160
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
165 170 175
Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
180 185 190
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
195 200 205
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
210 215 220
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg
225 230 235 240
Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys
245 250 255
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
260 265 270
Ser Leu Ser Leu Gly
275
<210> 22
<211> 277
<212> PRT
<213> synthetic construct
<400> 22
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Phe Leu Val Lys Gly Glu Leu Lys
20 25 30
Leu Leu Leu Arg Gly Ala Ala Ala Ala Lys Ser Ala Ala Ala Ala Ser
35 40 45
Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu
50 55 60
Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
65 70 75 80
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
85 90 95
Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
100 105 110
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
115 120 125
Ser Thr Tyr Arg Phe Glu Phe Val Leu Thr Gly Leu His Gln Asp Trp
130 135 140
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
145 150 155 160
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
165 170 175
Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
180 185 190
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
195 200 205
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
210 215 220
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg
225 230 235 240
Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys
245 250 255
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
260 265 270
Ser Leu Ser Leu Gly
275
<210> 23
<211> 277
<212> PRT
<213> synthetic construct
<400> 23
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Phe Leu Val Lys Gly Val Leu Lys
20 25 30
Leu Leu Leu Arg Gly Ala Ala Ala Ala Lys Ser Ala Ala Ala Ala Ser
35 40 45
Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu
50 55 60
Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
65 70 75 80
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
85 90 95
Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
100 105 110
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
115 120 125
Ser Thr Tyr Arg Ala Phe Glu Val Leu Thr Gly Leu His Gln Asp Trp
130 135 140
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
145 150 155 160
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
165 170 175
Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
180 185 190
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
195 200 205
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
210 215 220
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg
225 230 235 240
Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys
245 250 255
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
260 265 270
Ser Leu Ser Leu Gly
275
<210> 24
<211> 277
<212> PRT
<213> synthetic construct
<400> 24
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Phe Leu Val Lys Gly Val Leu Lys
20 25 30
Leu Leu Leu Arg Gly Ala Ala Ala Ala Lys Ser Ala Ala Ala Ala Ser
35 40 45
Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu
50 55 60
Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
65 70 75 80
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
85 90 95
Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
100 105 110
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
115 120 125
Ser Thr Tyr Arg Phe Glu Phe Val Leu Thr Gly Leu His Gln Asp Trp
130 135 140
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
145 150 155 160
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
165 170 175
Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
180 185 190
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
195 200 205
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
210 215 220
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg
225 230 235 240
Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys
245 250 255
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
260 265 270
Ser Leu Ser Leu Gly
275
<210> 25
<211> 276
<212> PRT
<213> synthetic construct
<400> 25
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Phe Leu Val Lys Gly Val Leu Leu
20 25 30
Leu Lys Lys Gly Ala Ala Ala Ala Lys Ser Ala Ala Ala Ala Ser Ala
35 40 45
Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe
50 55 60
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
65 70 75 80
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
85 90 95
Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val
100 105 110
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser
115 120 125
Thr Tyr Arg Ala Phe Glu Val Leu Thr Gly Leu His Gln Asp Trp Leu
130 135 140
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser
145 150 155 160
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
165 170 175
Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln
180 185 190
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
195 200 205
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
210 215 220
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu
225 230 235 240
Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser
245 250 255
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
260 265 270
Leu Ser Leu Gly
275
<210> 26
<211> 276
<212> PRT
<213> synthetic construct
<400> 26
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Phe Leu Val Lys Gly Val Leu Leu
20 25 30
Leu Lys Lys Gly Ala Ala Ala Ala Lys Ser Ala Ala Ala Ala Ser Ala
35 40 45
Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe
50 55 60
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
65 70 75 80
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
85 90 95
Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val
100 105 110
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser
115 120 125
Thr Tyr Arg Phe Glu Phe Val Leu Thr Gly Leu His Gln Asp Trp Leu
130 135 140
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser
145 150 155 160
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
165 170 175
Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln
180 185 190
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
195 200 205
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
210 215 220
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu
225 230 235 240
Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser
245 250 255
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
260 265 270
Leu Ser Leu Gly
275
<210> 27
<211> 277
<212> PRT
<213> synthetic construct
<400> 27
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala His Leu Val Lys Gly Ala Leu Lys
20 25 30
Leu Leu Leu Arg Gly Ala Ala Ala Ala Lys Ser Ala Ala Ala Ala Ser
35 40 45
Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu
50 55 60
Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
65 70 75 80
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
85 90 95
Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
100 105 110
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
115 120 125
Ser Thr Tyr Arg Ala Phe Glu Val Leu Thr Gly Leu His Gln Asp Trp
130 135 140
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
145 150 155 160
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
165 170 175
Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
180 185 190
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
195 200 205
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
210 215 220
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg
225 230 235 240
Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys
245 250 255
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
260 265 270
Ser Leu Ser Leu Gly
275
<210> 28
<211> 276
<212> PRT
<213> synthetic construct
<400> 28
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Ala Val Val
20 25 30
Lys Leu Lys Gly Ala Ala Ala Ala Lys Ser Ala Ala Ala Ala Ser Ala
35 40 45
Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe
50 55 60
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
65 70 75 80
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
85 90 95
Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val
100 105 110
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser
115 120 125
Thr Tyr Arg Ala Phe Glu Val Leu Thr Gly Leu His Gln Asp Trp Leu
130 135 140
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser
145 150 155 160
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
165 170 175
Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln
180 185 190
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
195 200 205
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
210 215 220
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu
225 230 235 240
Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser
245 250 255
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
260 265 270
Leu Ser Leu Gly
275
<210> 29
<211> 831
<212> DNA
<213> synthetic construct
<400> 29
cacgccgaag gaaccttcac ctcagatgtg tcatcatacc tcgaaggcga agccgccaag 60
gaattcatcg cattcctcgt gaaaggagca ctcaaactcc tcctccgtgg cgcggcggcg 120
gcgaaaagcg cggcggcggc gagcgccgaa tcgaaatatg gtcccccctg tccaccatgt 180
cccgctcccg aatttcttgg tggtccttct gtttttcttt ttcccccaaa accgaaagat 240
actcttatga tttccggcac tccagaggtt acttgtgttg ttgtggacgc ctcacaggag 300
gatccagagg cccaattcaa ttggtatgtc gatggcgtcg aagtccacaa cgccaaaacc 360
aaaccccgcg aagagcagtt caattctact tatcgtgcct tcgaagtcct tactggtctc 420
catcaagatt ggcttaatgg caaggaatac aaatgcaagg tctccaacaa aggcctcccc 480
tcatcaatcg aaaaaaccat ctcgaaagcc aaaggccaac cccgcgagcc ccaggtctat 540
actctccccc cctctcaaga agagatgacc aaaaaccagg cctcactcac gtgcctcgtc 600
aaaggattct acccgtccga tattgccgtc gagtgggaat caaacggaga gccagagaac 660
aactacaaaa ccaccccacc ggtgctcgat tcagatggct catttttcct ctactcacgt 720
ctcactgtcg acaaatcccg ctggcaggaa ggaaacgtct tttcatgttc agtcatgcac 780
gaagccctcc acaatcatta tacccaaaaa tcgctgtcac tcatgttggg a 831
<210> 30
<211> 20
<212> PRT
<213> synthetic construct
<400> 30
Met Gly Lys Leu Ile Phe Trp Leu Val Phe Trp Leu Thr Ile Phe Trp
1 5 10 15
Leu Gly Ser Ala
20
<210> 31
<211> 60
<212> DNA
<213> synthetic construct
<400> 31
atgggcaaac tcatattctg gcttgtgttt tggctgacta ttttttggct tggatcagct 60
Claims (5)
1.一种GLP-1类似物融合蛋白质,其由GLP-1类似物和免疫球蛋白Fc部分组成,两者通过肽接头融合,该融合蛋白质序列选自SEQ ID NO:17-28。
2.一种多核苷酸,其编码权利要求1所述的融合蛋白质。
3.一种载体,其包含权利要求2的多核苷酸。
4.一种宿主细胞,其包含权利要求3的载体,为CHO细胞或NSO细胞。
5.权利要求1所述的融合蛋白质用于生产治疗非胰岛素依赖性糖尿病的药物的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811472291.9A CN111269321B (zh) | 2018-12-04 | 2018-12-04 | 一种glp-1类似物融合蛋白质 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811472291.9A CN111269321B (zh) | 2018-12-04 | 2018-12-04 | 一种glp-1类似物融合蛋白质 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111269321A CN111269321A (zh) | 2020-06-12 |
CN111269321B true CN111269321B (zh) | 2023-05-12 |
Family
ID=70994651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811472291.9A Active CN111269321B (zh) | 2018-12-04 | 2018-12-04 | 一种glp-1类似物融合蛋白质 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111269321B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114410676A (zh) * | 2020-10-28 | 2022-04-29 | 中国科学院植物研究所 | 降血糖功能性水稻材料的创制方法及应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1703424A (zh) * | 2002-10-11 | 2005-11-30 | 株式会社三和化学研究所 | Glp-1衍生物及其经粘膜吸收的制剂 |
CN101328221A (zh) * | 2008-04-14 | 2008-12-24 | 中国药科大学 | 一种降糖多肽融合蛋白及其衍生物的结构及用途 |
WO2009058734A4 (en) * | 2007-10-30 | 2009-07-23 | Univ Indiana Res & Tech Corp | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
CN106397569A (zh) * | 2015-08-01 | 2017-02-15 | 深圳红石科创生物科技发展有限公司 | 一种治疗代谢疾病的突变细胞因子融合蛋白 |
CN108424460A (zh) * | 2017-02-13 | 2018-08-21 | 成都贝爱特生物科技有限公司 | GLP-1类似物和davalintide类似物的融合蛋白制备及其用途 |
-
2018
- 2018-12-04 CN CN201811472291.9A patent/CN111269321B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1703424A (zh) * | 2002-10-11 | 2005-11-30 | 株式会社三和化学研究所 | Glp-1衍生物及其经粘膜吸收的制剂 |
WO2009058734A4 (en) * | 2007-10-30 | 2009-07-23 | Univ Indiana Res & Tech Corp | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
CN101328221A (zh) * | 2008-04-14 | 2008-12-24 | 中国药科大学 | 一种降糖多肽融合蛋白及其衍生物的结构及用途 |
CN106397569A (zh) * | 2015-08-01 | 2017-02-15 | 深圳红石科创生物科技发展有限公司 | 一种治疗代谢疾病的突变细胞因子融合蛋白 |
CN108424460A (zh) * | 2017-02-13 | 2018-08-21 | 成都贝爱特生物科技有限公司 | GLP-1类似物和davalintide类似物的融合蛋白制备及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CN111269321A (zh) | 2020-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Therapeutic peptides: current applications and future directions | |
CN101974090B (zh) | Glp-1类似物融合蛋白质 | |
CN101389648B (zh) | 肽胃泌酸调节素衍生物 | |
JP2019213548A (ja) | 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物 | |
RU2269354C2 (ru) | Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения | |
ES2535358T3 (es) | Bibliotecas de proteínas de fusión de transferrina | |
US20060122371A1 (en) | Process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same | |
CZ171492A3 (en) | Polypeptide, process of its preparation, pharmaceutical composition containing thereof and its use as an intermediate for insulin preparation | |
WO2011153965A1 (zh) | Exendin-4及其类似物的融合蛋白,其制备和应用 | |
WO2021068986A1 (zh) | 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用 | |
US20070293429A1 (en) | Vasoactive Intestinal Polypeptide Compositions | |
CN113292646B (zh) | Glp-1/胰高血糖素双重激动剂融合蛋白 | |
JPH04503812A (ja) | メラニン濃縮ホルモンおよびそれを用いた処置法 | |
CA2175786A1 (en) | Igf-1 superagonists | |
CN110172103B (zh) | GLP-1类似物-Fc融合蛋白及其制备方法和用途 | |
WO2021147869A1 (zh) | 利拉鲁肽衍生物及其制备方法 | |
CN111269321B (zh) | 一种glp-1类似物融合蛋白质 | |
CN111269312B (zh) | 一种异源融合蛋白质 | |
WO2004048401A1 (ja) | ペプチド及びこれを含む医薬組成物 | |
WO2016119399A1 (zh) | 一种多肽复合物作为多肽或蛋白质药物载体的应用、方法及其融合蛋白复合物 | |
JPH0786120B2 (ja) | ポリペプチド | |
CN106008717B (zh) | 一种长效重组glp-1融合蛋白及其制备方法和用途 | |
CN1962695A (zh) | 类胰高血素肽-1融合蛋白及其制备和用途 | |
EP0315118A2 (en) | DNA coding for endothelin and use thereof | |
CN117756913A (zh) | 一种新型长效多肽化合物、组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |